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Jacquelyn D. Lajiness 
SHP2 DELETION IN POST-MIGRATORY NEURAL CREST CELLS RESULTS 
IN IMPAIRED CARDIAC SYMPATHETIC INNERVATION 
 
Autonomic innervation of the heart begins in utero and continues during the 
neonatal phase of life. A balance between the sympathetic and parasympathetic 
arms of the autonomic nervous system is required to regulate heart rate as well 
as the force of each contraction. Our lab studies the development of sympathetic 
innervation of the early postnatal heart in a conditional knockout (cKO) 
of Src homology protein tyrosine phosphatase 2 (Shp2). Shp2 is a ubiquitously 
expressed non-receptor phosphatase involved in a variety of cellular functions 
including survival, proliferation, and differentiation. We targeted Shp2 in post-
migratory neural crest (NC) lineages using our novel Periostin-Cre. This resulted 
in a fully penetrant mouse model of diminished cardiac sympathetic innervation 
and concomitant bradycardia that progressively worsen.  
 
Shp2 is thought to mediate its basic cellular functions through a plethora of 
signaling cascades including extracellular signal-regulated kinases (ERK) 1 and 
2. We hypothesize that abrogation of downstream ERK1/2 signaling in NC 
lineages is primarily responsible for the failed sympathetic innervation phenotype 
observed in our mouse model. Shp2 cKOs are indistinguishable from control 
littermates at birth and exhibit no gross structural cardiac anomalies; however, in 
vivo electrocardiogram (ECG) characterization revealed sinus bradycardia that 
 ix   
 
develops as the Shp2 cKO ages. Significantly, 100% of Shp2 cKOs die within 3 
weeks after birth. Characterization of the expression pattern of the sympathetic 
nerve marker tyrosine hydroxylase (TH) revealed a loss of functional sympathetic 
ganglionic neurons and reduction of cardiac sympathetic axon density in Shp2 
cKOs. Shp2 cKOs exhibit lineage-specific suppression of activated pERK1/2 
signaling, but not of other downstream targets of Shp2 such as pAKT 
(phosphorylated-Protein kinase B). Interestingly, restoration of pERK signaling 
via lineage-specific expression of constitutively active MEK1 (Mitogen-activated 
protein kinase kinase1) rescued TH-positive cardiac innervation as well as heart 
rate. These data suggest that the diminished sympathetic cardiac innervation and 
the resulting ECG abnormalities are a result of decreased pERK signaling in 
post-migratory NC lineages. 
 
David A. Ingram, Jr., M.D., Administrative Chair 
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INTRODUCTION 
 
The neural crest 
The neural crest (NC) is a multipotent and transient migratory embryonic lineage 
that gives rise to a wide variety of cell types, tissues, and organs1-4. The NC is 
derived from the ectoderm, but is often referred to as the “fourth germ layer” 
because of the key role it plays in development. NC cells are required at different 
developmental stages for normal development of diverse tissues such as the 
facial skeleton, melanocytes, as well as the dermis, smooth muscle and adipose 
tissue associated with the skin in the head and neck region, the outflow tract 
septum of the heart, the smooth muscle associated with arteries derived from the 
aortic arches, and the peripheral nervous system (including the sensory, enteric, 
and autonomic nervous systems)3, 5-10. NC cells originate within early embryo 
neural folds. Although these cells are epithelial in nature while in the neural folds, 
they undergo epithelial-mesenchymal transition (EMT), delaminate from the 
neural folds, and migrate to target sites throughout the body where they 
differentiate into a variety of different cell types. The processes of NC induction, 
delamination, EMT, migration, and differentiation are extremely complex and 
subject to many influencing factors such as bone morphogenic proteins and 
various growth factors2, 10. 
 
The NC is often categorized by the rostral-caudal region from which the NC cells 
migrate. There are five regional classifications that correlate roughly with 
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functional designations: cranial, cardiac, vagal, trunk, and sacral NC (Figure 1). 
Cranial NC cells originate from the forebrain, midbrain and hindbrain regions of 
the neuroepithelium. The cranial NC will give rise to the pharyngeal arches which 
will eventually form the connective tissue and skeletal framework of the face and 
middle ear as well as the cranial nerves and associated glia, and the thymus, 
parathyroid, and thyroid glands9, 11. The cardiac NC develops from the region 
associated with somite 1-3 in embryos. These cells colonize the aortic arches, 
the endocardial cushions, and the outflow tract of the heart eventually 
contributing to aortic arch remodeling, valve development and outflow tract 
septation events4, 12. Abnormalities in the cardiac NC can lead to developmental 
cardiac defects such as persistent truncus arteriosus, double outlet right 
ventricle, and transposition of the great arteries (reviewed in 13). The cardiac NC 
region overlaps with the vagal NC which extends from somite 1-7. The vagal NC 
cells, in conjunction with the sacral NC (posterior to somite 28), migrate to the gut 
and give rise to the enteric ganglia (parasympathetic in nature). Failure of the 
vagal and sacral NC cells to migrate results in loss of enteric ganglia. In the 
absence of ganglia, peristaltic movement in the intestine is not established which 
can result in obstruction14-16. The remaining NC population (somites 8-28) is 
collectively referred to as trunk NC which migrate along one of two migratory 
pathways. The trunk NC cells that migrate dorsolaterally give rise to many of the 
pigmented cells found throughout the body such as melanocytes. The remaining 
trunk NC cells migrate along the ventral pathway and give rise to the adrenal 
medulla (specifically derived from cells arising from somite 18-24), along with the 
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majority of the peripheral nervous system including the dorsal root ganglia (DRG) 
and associated sensory nervous system, sympathetic, and parasympathetic 
nervous systems as well as associated Schwann cells (SCs). 
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Figure 1. Subsets of NC and the structures derived from them. Figure 
depicts a schematic of a developing embryo (~E10/11). The cranial NC cells are 
derived from the forebrain, midbrain, and hindbrain (represented in light blue). 
These cells give rise to the pharyngeal arches which form the components listed. 
The somites of the developing embryo are depicted in orange. Cardiac NC cells 
(somites 1-3; red) give rise to the cardiac outflow tract (OFT), aortic arch arteries 
(AAA) and the cushions which will form the valves of the heart. Vagal NC 
(somites 1-7; purple) and sacral NC (after somite 28; blue) cells collectively 
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contribute to the innervation of the gut. Trunk NC cells (somites 8-28; green) give 
rise to the various components listed.  
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Due to the multistep process of NC morphogenesis (i.e. delamination, EMT, 
migration, and differentiation), NC cells are especially vulnerable to both 
environmental and genetic influences. Many congenital birth defects are thought 
to be due to aberrant NC morphogenesis17, and NC ablation can result in various 
structural abnormalities including craniofacial defects such as mandibular 
hypoplasia and cleft palate, myelination and innervation defects, several different 
cardiac defects (reviewed in 17) as well as abnormal electrical function of the 
embryonic heart18, 19. The extremely versatile yet susceptible nature of the NC 
lineage makes it an incredibly interesting area of study; however, investigations 
are often limited by the availability of genetic tools and the severity of the 
phenotypes observed as many mouse models with altered NC development are 
embryonically lethal and thus more subtle phenotypes or those occurring later in 
development go unexamined. 
 
Various Cre lines instituted in NC studies 
Cre recombinase is an enzyme used for genetic recombination of genomic DNA 
in animal models. Sophisticated mouse models have been developed where the 
spatiotemporal expression of Cre recombinase (referred to as “Cre” for short) is 
controlled by the promoter that drives its expression. By selecting a promoter that 
has a restricted temporal and anatomic expression pattern, it is possible for 
researchers to generate an animal model with precise genetic manipulation. A 
“Cre line” is a mouse line carrying a particular promoter used to drive Cre 
expression. This mouse line can be crossed to any number of transgenic mouse 
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lines with a floxed region of DNA (i.e. DNA flanked by LoxP sites) to drive genetic 
recombination. There is more than one way that Cre can be used as a genetic 
tool; however, in this study it is used to excise genomic DNA that is surrounded 
by introduced LoxP sites. A LoxP site is a palindromic sequence of DNA that is 
recognized and spliced by Cre. Once Cre is expressed in a cell, it permanently 
alters genomic DNA in that cell specifically20. Because genomic DNA is altered, 
any progeny of a cell that expressed Cre is also genetically modified even if Cre 
itself is never expressed in the progeny. 
 
As spatiotemporal precision is an essential aspect to Cre-mediate genetic 
recombination technology, a reporter system capable of indicating when and 
where Cre is expressed was developed. The reporter system utilized in this study 
is the ROSA/LacZ reporter system (illustrated in Figure 5). Briefly, a transgene 
containing the constitutively active ROSA26 promoter, a neo cassette flanked by 
LoxP sites, and the lacZ gene followed by a polyadenylation sequence is 
introduced in a mouse line21. When crossed onto the background of a Cre-
expressing mouse line, Cre will delete the neo cassette and allow for 
transcription of the lacZ gene which encodes β-galactosidase. β-galactosidase 
expression, thus, occurs only in cells expressing Cre and can then be detected 
via X-Gal staining. Thus, all genetically modified cells can be identified. This 
technique is referred to as lineage mapping. 
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There are several mouse lines in which Cre recombinase is expressed in 
different subsets of developing NC cells at varying time points throughout 
development. One of the earliest Cre lines to be expressed in a significant NC 
population is AP2-α-Cre. Cre is expressed as early as E7 in the cranial NC which 
contributes to all pharyngeal arches and in the caudal ectoderm overlying what 
will become the pharyngeal arches22, 23. AP2-α-Cre is a useful tool for extremely 
early investigations into development; however, its utility in NC investigations is 
often limited by the confounding factor that it is also expressed in the ectoderm. 
As the ectoderm releases factors critical to NC survival, migration, and 
differentiation, it becomes difficult to determine whether a genetic alteration 
driven by AP2-α-Cre causes a primary defect in the NC itself to give rise to a 
particular phenotype or if the observed effect is secondary in nature due to an 
alteration of the neural ectoderm overlying the neural crest which indirectly 
affects the NC cells. 
 
The “classical” NC Cre line is Wnt1-Cre in which Cre is expressed in the dorsal 
neural folds and neural tube prior to delamination and emigration of the NC 
(E8)23-25. At E8.5 Cre is expressed in the majority of migratory NC cells and the 
complete pattern of expression is observed by E11.523, 24, 26. In the Wnt1-Cre 
model, many NC derived tissues express Cre including the pharyngeal arches, 
outflow tract of the heart, aorto-pulmonary septum, dorsal root ganglia and 
peripheral nervous system as well as the Schwann cells supporting and 
myelinating those neurons23. This is the most complete and most widely used 
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Cre line for NC studies, however it does have its limitations. For example, there 
have been reports that Wnt1-Cre can induce phenotypes by ectopically activating 
endogenous Wnt signaling25. Furthermore, Cre expression in such a wide array 
of tissues from an early age (as early as E8) results in many phenotypes that are 
embryonically lethal and thus will not allow for investigation of more subtle 
phenotypes or phenotypes that arise postnatally27. 
 
A tamoxifen inducible form of Wnt1-Cre does exist which enables researchers to 
activate Cre expression at any time after the onset of Wnt-1 promoter activation. 
However, Cre is only expressed in cells that are actively utilizing the Wnt-1 
promoter at the time of administration of tamoxifen. Further, the recombination 
efficiency is drastically reduced and the level of tamoxifen needed to induce 
recombination boarders on the level that will interfere with pregnancy24. While 
this Cre system may have specific applications, its utility in comprehensive NC 
development studies is tenuous. 
 
Another Cre transgenic line that is expressed in NC lineages is the P0-Cre. Cre 
is expressed in NC derivatives such as the DRG, the sensory and enteric 
nervous systems, and pharyngeal arch derived craniofacial mesenchyme from 
E9 onward23, 28. In this model, the complete Cre expression pattern is observed 
by E12.5. Cre is expressed in a smaller subset of NC than observed in the Wnt1-
Cre line. Furthermore, unlike the Wnt1-Cre line, the P0-Cre line expresses Cre in 
the notochord which is not derived from the NC28. 
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There are two different Cre lines in which Cre expression is driven by the nestin 
gene promoter. Nestin1-Cre is expressed in several NC and non-NC lineages. 
The earliest Cre expression detected by reporter gene expression occurs at 
E7.5-8 and is observed in specified areas of the embryo as well as in extra-
embryonic mesenchyme29. The branchial arches express Cre E8-10.5, and by E9 
the heart contains Cre-positive cells. However, several non-NC lineages such as 
the entire central nervous system and pancreatic progenitors also express Cre by 
E14.5-15.529. Unfortunately, although being expressed in NC lineages at 
important times, Cre expression in such a wide variety of non-NC lineages 
precludes Nestin1-Cre from being informative about isolated NC defects. 
Similarly, in the Nestin2-Cre Cre line, Cre is expressed in both NC lineages as 
well as the central nervous system (non-NC-derived). By E11.5 the DRG (NC-
derived) as well as the ventricular zone of the telenecephalon and spinal cord 
(central nervous system) are Cre-positive30. 
 
In the Advillin-Cre model, Cre is expressed in NC-derived structures such as all 
peripheral sensory neurons including DRG, trigeminal ganglia, and nodose 
ganglia as well as the superior cervical ganglia (sympathetic nervous system) 
from E14.5-16.531. Cre expression is also detected in the midbrain, brainstem, 
and tongue (non-NC-derived)31. As Advillin-Cre is expressed in a small subset of 
NC-lineages and is only activated relatively late in development, it, like all other 
Cre lines, has limitations in its applicability to the study of NC development. 
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Collectively, current transgenic lines expressing Cre in NC-derived tissues cover 
a relatively wide range of tissue subsets and developmental time points. Certain 
lineages such as the derivatives of the pharyngeal arches and the sensory 
nervous system and corresponding DRG are well represented at varying time 
points whereas other lineages such as the sympathetic nervous system have 
only partial expression or limited time points at which developmental requirement 
for particular genes can be investigated. As E8-E11 is a crucial developmental 
window in which NC cells migrate throughout the body and differentiate into 
various tissues, the more genetic tools available to manipulate NC cells in this 
timeframe, the more detailed our knowledge of NC cellular processes will 
become. The work herein describes using a Cre line developed in our lab 
(Periostin-Cre) to investigate the development of NC derivatives specifically 
focusing on the sympathetic arm of the autonomic nervous system. 
 
Autonomic nervous system 
The autonomic nervous system (ANS), as a subset of the peripheral nervous 
system, is derived from the NC. The ANS itself is divided into two diametrically 
opposed branches: the sympathetic and parasympathetic nervous systems. The 
sympathetic innervation ramps up the “fight or flight” responses while the 
parasympathetic innervation reverses these responses in favor of promoting “rest 
and digest” functions32. Together, these two arms maintain homeostasis; regulate 
the organism’s responses to exercise, stress, and/or injury; and interact with the 
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endocrine system to control reproduction33. The word “autonomic” means “self-
governing” and that is precisely what this aspect of the nervous system does; it 
controls all of the elements of daily life that you don’t have to think about. It 
regulates blood pressure and heart rate, coordinates basal respiratory rate, 
controls body temperature, adjusts urinary output and salt retention, facilitates 
digestion and propulsion of food through the digestive tract, and maintains blood 
glucose levels33, 34. 
 
The classic structure of the ANS is a two-neuron chain. The cell body of the first 
neuron (the preganglionic fiber) resides in the interomediolateral horn of the 
spinal cord and projects out its axon to a peripheral ganglia where it synapses on 
the cell body and/or dendrites of the second neuron (the postganglionic fiber)33-
35. The postganglionic fiber then synapses directly onto the target organ. 
Typically sympathetic neurons have short preganglionic axons and long 
postganglionic axons (i.e. the peripheral ganglia is located near the spinal cord) 
while the opposite is true for the parasympathetic neurons (the peripheral ganglia 
is located near/on the target organ)34. However, this does not hold true for some 
organs such as the heart and the gut which have more complex interactions 
between the sympathetic and parasympathetic innervation33, 36-42. 
 
There are two main neurotransmitters that transduce signals in the ANS: 
acetylcholine and norepinephrine. Acetylcholine is released at all ganglionic 
synapses (between the pre- and postganglionic fibers) and is recognized by 
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nicotinic cholinergic receptors on the postganglionic neuron43. Parasympathetic 
postganglionics also release acetylcholine which achieves its effects on the 
target organ through muscarinic receptors. In contrast, most sympathetic 
postganglionics release norepinephrine which signals through α–adrenergic or 
β–adrenergic receptors depending upon the tissue44, 45. The sympathetic 
innervation to the sweat glands and some blood vessels are important 
exceptions as they signal through the acetylcholine/muscarinic receptor pathway 
despite being part of the sympathetic nervous system33. All adrenergic receptors 
signal through G-proteins and primarily result in altered cAMP levels by either 
stimulating adenylate cyclase to increase cAMP levels or inhibiting it to decrease 
cAMP levels. Specificity for how an individual organ responds to sympathetic 
stimulation is achieved through which subsets of receptors (α1, α2, β1, and β2) 
are expressed and at what concentrations. Thus, the same sympathetic stimulus 
can effect different physiological changes in different tissues43, 45. 
 
α1–adrenergic receptors are located on peripheral smooth muscle cells and 
when stimulated with either epinephrine or norepinephrine result in the 
contraction of those muscles through increasing calcium levels33, 46. 
Physiologically, this results in dilation of the pupils and vasoconstriction of blood 
vessels. α2–adrenergic receptors serve and important negative feedback role in 
the autonomic nervous system47, 48. These receptors are located on vascular 
prejunctional synapses, and when stimulated with epinephrine or extremely high 
levels of norepinephrine, they signal through an inhibitory G-protein which inhibits 
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adenylate cyclase and decreases cAMP levels preventing further release of 
norepinephrine at that synapse49. β1–adrenergic receptors are expressed 
predominantly in the heart and are responsible for many of the “fight or flight” 
systemic response associated with sympathetic stimulation such as increased 
heart rate and cardiac output35, 50. These effects are achieved through an 
increase in cAMP levels in the pacemaker cells of the heart (the SA node) as well 
as in the cardiomyocytes. The elevated cAMP levels lead to an increase not only 
the heart rate but also the strength of each contraction. And finally, β2–
adrenergic receptors are located on peripheral smooth muscle and when 
stimulated result in elevated cAMP levels leading to the relaxation of the 
associated smooth muscle cells34, 51. This allows for bronchodilation to increase 
oxygen intake as well as vasodilation to provide increased circulation to skeletal 
muscles in preparation for strenuous activity. These receptors are much more 
sensitive to epinephrine (released by the adrenal gland) as opposed to 
norepinephrine (released by sympathetic neurons)33, 45. 
 
While acetylcholine is commonly produced by many subsets of neurons, 
norepinephrine is unique to sympathetic neurons. Therefore, expression of 
enzymes critical in the synthetic pathway of catecholamines (norepinephrine and 
epinephrine) can be used to identify sympathetic innervation. One such enzyme 
is tyrosine hydroxylase (TH; the rate-limiting enzyme for catecholamine 
synthesis). TH catalyzes the conversion of tyrosine to L-DOPA (a key 
intermediate of catecholamine synthesis) and is commonly used as a definitive 
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marker of sympathetic innervation52-55. A less commonly used, but more specific 
marker of sympathetic innervation is dopamine β-hydroxylase (DβH). DβH 
converts dopamine to norepinephrine and is only expressed in noradrenergic 
neurons and adrenal chromaffin cells. A small population of TH-positive, DβH-
negative neurons does exist. This population are dopaminergic neurons and are 
primarily located in the central nervous system and the enteric nervous system56. 
 
Development of cardiac sympathetic innervation   
Although autonomic innervation of the heart begins in utero, functional 
neurocardiac coupling continues postnatally. Autonomic imbalance and irregular 
cardiac innervation density can result in deadly consequences such as cardiac 
arrhythmias, heart failure, and sudden cardiac death57-60. While a balance 
between the sympathetic and parasympathetic arms of the autonomic nervous 
system is required to regulate heart rate, conduction velocity, and the force of 
each contraction, sympathetic tone predominates in determining the basal heart 
rate in rodents. This means that in a rodent if the heart were removed from all 
sympathetic and parasympathetic input, it would beat slower. This is because the 
stimulus to beat faster from the sympathetic innervation is, at rest, stronger than 
the parasympathetic stimulus to slow the heart rate. Therefore, removing 
sympathetic input has a greater physiologic effect on heart rate, and the heart 
rate will decrease as a result. 
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The sympathetic nervous system arises from the neural crest lineage. In the case 
of sympathetic neurons innervating the heart, trunk NC cells delaminate and 
migrate ventrally through the somites to establish the sympathetic trunk ganglia 
near the dorsal aorta8, 54, 61, 62. Post-migration, cross-regulatory transcription 
factors such as Mash1, Phox2a and 2b as well as Gata363-69 are temporarily 
expressed. Expression of these transcription factors drives NC cells to acquire a 
neuronal fate and eventually to differentiate into sympathetic neurons expressing 
both neuron specific β-tubulin (NSβT) and TH 70-75. Subsequently, a subset of 
sympathetic NC cells undergoes a second migration to the cervicothoracic and 
intrinsic cardiac ganglia to establish populations of sympathetic neurons which 
contribute to the cardiac plexus or “heart brain” 8, 40, 41. Recent studies exploring 
the extensive complexity of autonomic cardiac innervation revealed multiple 
levels of regulation and interaction between parasympathetic and sympathetic 
arms of autonomic innervation that converges in the “heart brain” to control 
cardiac function36-42. This network seems to be particularly influential and 
dynamic in the first few weeks of life making our Shp2 cKO model ideally situated 
to investigate this important developmental stage. 
 
Sympathetic (i.e. TH-positive) innervation is first observed at the base (near the 
aorta and pulmonary artery) of the heart around embryonic (E) day 13.5. This 
innervation then extends onto the surface of the atria and eventually to the 
ventricles before following blood vessels into the atrial and ventricular walls to 
innervate the myocardium and project to the sinoatrial (SA) and atrioventricular 
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(AV) nodes76. Establishment of the sympathetic innervation of the heart is 
achieved gradually over a month, beginning in utero at E13.5 and culminating at 
approximately 3 weeks after birth. 
 
Sympathetic innervation to the SA and AV nodes serves two purposes. The SA 
node is the pacemaker of the heart (the collection of cells that generates the 
action potential that results in the depolarization of the atria—corresponding to 
the P-wave of an ECG; Figure 2). Sympathetic stimulation of the SA node results 
in an overall increase in heart rate by decreasing the amount of time between 
each P-wave. The AV node, under normal physiological conditions, is 
responsible for delaying the action potential after the atria but before the 
ventricles so that the atria have enough time to finish emptying all of the blood 
that they contain into the ventricles before the ventricles begin contracting (it 
essentially controls the length of the PR interval; Figure 2). Sympathetic 
stimulation of the AV node also serves to increase heart rate by decreasing the 
duration of this “pause”.  
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Figure 2. Standard ECG trace. The standard ECG is broken up into three main 
waveforms and two clinically relevant intervals: 
 
The P-wave (green) corresponds to the electrical depolarization of the atria. The 
action potential responsible for generating the P-wave is initiated by SA node and 
disseminates throughout the atria to signal a coordinated contraction. An absent 
P-wave indicates abnormal SA node function. 
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The PR-interval corresponds to conduction delay at the AV node. A prolonged 
PR-interval indicates some degree of AV-block which if progresses, can result in 
arrhythmias and sudden death. 
 
The QRS complex (orange) corresponds to the electrical depolarization of the 
ventricle. 
 
The QT-interval corresponds to the length of the mechanical contraction of the 
ventricles. Prolongation or abbreviation of the QT-interval can predispose to 
ventricular tachycardia which can progress to ventricular fibrillation and sudden 
death. 
 
The T-wave (blue) corresponds to ventricular repolarization. 
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Although present from in utero stages, the sympathetic innervation of the heart is 
not functionally relevant (i.e. does not control heart rate) until the second week of 
postnatal life in rodents37, 53, 77. While the number of primary dendrites emanating 
from sympathetic ganglia is set in the first postnatal week of life, the adult pattern 
of innervation achieved through extension and further branching of the primary 
dendrites is not fully formed until three weeks after birth37, 78-80. Nerve growth 
factor (NGF) is the signaling factor that primarily determines the density and 
complexity of sympathetic innervation and is absolutely essential in the first 
several weeks of postnatal life79. 
 
Role of NGF in establishment and maintenance of sympathetic innervation 
The establishment of sympathetic innervation requires NGF production by the 
target organ—the myocardium in the case of the heart. NGF is the main 
neurotrophic factor in establishing and maintaining sympathetic innervation as 
well as a subpopulation of sensory neurons in the dorsal root ganglia27, 81. In vitro 
studies have shown that NGF stimulates the differentiation/neurite outgrowth of 
sympathetic neurons through the Shp2/ERK pathway while mediating the 
survival of those same neurons through the PI3K/AKT pathway82-89. Interestingly, 
NGF is not required early in embryonic development nor in adult animals once 
the sympathetic innervation has been established. However, NGF signaling is 
required for establishment of sympathetic innervation from E16.5 onward90 and is 
essential for the survival of sympathetic neurons from P1-P4091. Understanding 
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this critical developmental window (from E16.5-1 month after birth) is key to 
investigations into sympathetic innervation. 
 
NGF binds to its high-affinity receptor tropomyosin-related receptor A (TrkA). 
TrkA then results in the formation of a signaling complex including Src homology 
protein tyrosine phosphatase 2 (Shp2) which leads to activation of the Ras-RAF-
MEK signaling cascade eventually resulting in sustained extracellular signal-
regulated kinase (ERK) activation through phosphorylation. Once ERK is 
phosphorylated, it translocates to the nucleus where it modulates expression of 
genes controlling basic cellular functions such as proliferation and 
differentiation86, 92. Interestingly, mutating mitogen-activated protein kinase 
kinase (MEK) so that it is incapable of phosphorylating ERK blocks sympathetic 
neuronal differentiation in the model cell line (PC12 cells). Conversely, 
introducing an activating mutation in MEK induces differentiation and neurite 
outgrowth in sympathetic neurons even in the absence of differentiation factors 
such as NGF86. These experiments have shown that, at least in vitro, ERK 
phosphorylation is both necessary and sufficient for sympathetic neuron 
differentiation as defined by neurite outgrowth. 
 
Interruption of the NGF signaling pathway at either the ligand (NGF) or receptor 
(TrkA) level results in pups that are viable at birth without any gross defects. 
However, the pups fail to gain weight, have decreased cross-sectional area of 
sympathetic neurons in ganglia and fewer dendrites, exhibit total loss of 
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sympathetic innervation by 10 days after birth, and all are dead by 4 weeks after 
birth (Ngf null) or ~8 weeks after birth (TrkA null)27, 93-95. NGF deprivation studies 
in which NGF antiserum was administered revealed that peripheral sympathetic 
innervation is affected by loss of NGF in the postnatal period but not in 
adulthood. This result indicates that there exists a critical window for NGF action 
and establishment of sympathetic innervation94, 96. Conversely, administering 
NGF to developing pups resulted in the expansion of arborization arising from 
sympathetic ganglia. Specifically, there was an increase in the number of primary 
dendrites as well as an increase in their length and number of branch points79. In 
vitro studies indicate that NGF administration promotes differentiation and thus 
neurite outgrowth and arborization but halts cellular division86. Other models of 
altered sympathetic innervation including a p75 (a low-affinity receptor of NGF) 
null mouse as well as a Sema3a (a neural chemorepellent for sensory and 
sympathetic axons) null mouse and mouse model involving NC-restricted 
deletion of the Sema3A receptor Nrp1 all result in diminished sympathetic 
innervation of the heart and subsequent bradycardia38, 97, 98. Collectively, these 
studies illustrate that interruptions in NGF signaling at the ligand or receptor 
disturb sympathetic innervation which, among other effects, can lead to sinus 
bradycardia. In the current study we are interested in understanding what effect 
downstream interruptions in NGF signaling (specifically at the level of signal 
transduction through Shp2) will have on the development of sympathetic 
innervation particularly in the heart. 
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Shp2 signaling and roles in development 
Shp2 is a ubiquitously expressed non-receptor phosphatase containing two N-
terminal Src homology2 (SH2) domains, a central protein tyrosine phosphatase 
(PTP) catalytic domain, and a C-terminus with tyrosyl phosphorylation sites and a 
proline-rich domain99, 100. It is involved in a variety of cellular functions including 
survival, proliferation, and differentiation100-104. Shp2 gain-of-function mutations 
account for approximately 50% of Noonan syndrome (NS, OMIM 163950) 
characterized by postnatal reduced growth, dysmorphic facial features, skeletal 
abnormalities, and cardiac defects105. Conversely, loss of Shp2 catalytic activity 
results in LEOPARD syndrome (LS, OMIM 151100) which is characterized by 
lentigines (dark, freckle-like lesions covering the skin), electrocardiographic 
(ECG) abnormalities, ocular hypertelorism (wide-set eyes), pulmonary stenosis, 
abnormal genitalia, growth retardation resulting in short stature, sensory neural 
deafness as well as other neurologic and cardiac defects including hypertrophic 
cardiomyopathy106. It has often been commented in the literature how LS and NS 
have striking clinical similarities despite manifesting opposite effects on Shp2 
activity and downstream signaling cascades. This is predominantly thought to 
reflect a narrow physiologic range of downstream MAPK signaling that is 
conducive for proper development102, 107. 
 
There are seven Shp2 mutations associated with LS, all of which are 
concentrated in the catalytic core of the protein. These mutations have been 
shown in vitro to cause a decrease in catalytic activity of Shp2 and diminished 
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MAPK signaling102, 108, 109; however there is still debate as to the mechanism for 
how Shp2 facilitates Ras/MAPK activation. It has been hypothesized that Shp2 
can act by any of the following mechanisms or a combination thereof: 
dephosphorylating binding sites on RasGAP receptors, inactivating Grb2/Sos 
inhibitors, and/or activating Src family kinases resulting in sustained Ras and 
subsequent ERK activation102, 110, 111. While the specific mechanism has yet to be 
elucidated, it is known that activation of Shp2 via a ligand binding a receptor 
tyrosine kinase (RTK) results in increased RAS activity and subsequent 
phosphorylation of ERK1/2 which then translocate to the nucleus to alter 
transcription and regulate cellular processes (Figure 3). 
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Figure 3. Schematic of Shp2/MAPK signaling cascade. A ligand (i.e. growth 
factor) binds to a receptor tyrosine kinase (RTK) which is associated with a 
complex including Shp2. Propagation of signaling results in localization of Ras to 
the membrane where GDP is exchanged for GTP. Ras bound to GTP activates 
RAF via phosphorylation which continues the activating phosphorylation cascade 
through MEK and ERK. Once phosphorylated, ERK translocates to the nucleus 
where it regulates transcription to alter cellular survival, proliferation, and 
differentiation. Schematic based off of work detailed in Rosario et al., 2007 92. 
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It is generally accepted that many of the phenotypes observed in models of 
altered Shp2 signaling are a direct result of aberrant pERK levels. By extension, 
this would suggest that many of the clinical manifestations of diseases such as 
LS and NS are likewise associated with altered MAPK signaling107. LS itself is 
characterized by a constellation of symptoms such as heart defects and ECG 
abnormalities including sinus bradycardia—although the ECG anomalies 
observed are often complicated by structural defects112, 113. LS patients can 
exhibit sudden cardiac arrest associated with ECG anomalies; however, they 
usually have a complex presentation including hypertrophic cardiomyopathy114-
116. 
 
Indeed, other related disorders (e.g. Costello, Cardiofaciocutaneous, 
Neurofibromatiosis type-1, and Legius syndromes) all share clinical overlap and 
possibly a common pathogenetic mechanism with LS and NS, thus they have 
been grouped into the neurocardiofacialcutaneous syndrome family (or the RAS-
opathies)117, 118. We are not proposing that Shp2;Periostin-Cre conditional knock 
outs (cKOs) are a mouse model for NS, LS or other RAS-opathies. Instead, we 
are hypothesizing that the arrhythmogenesis observed in some of these patients 
may be due to abnormal Shp2 function and misregulation of downstream MAPK 
signaling during sympathetic nervous system innervation of the heart.  
 
Although Shp2 has been shown to signal through several different cascades 
such as PI3K, MAPK, NFAT, and JAK/Stat104; ERK1 and 2 are thought to be 
27 
 
particularly important for mediating aberrant Shp2 phenotypes119, 120. This was 
elegantly demonstrated via the rescue of various Shp2 gain-of-function 
phenotypes by decreasing pERK signaling through genetic as well as 
pharmacologic manipulation119, 120. Specifically in sympathetic neurons, Shp2 
and downstream activation of ERK have been shown to be required for 
differentiation (as indicated by neurite outgrowth) in vitro86, 121, 122. Shp2 and 
downstream targets such as ERK are extremely important in the context of 
cardiac development and the mechanism of several human diseases, but our 
understanding of the direct roles of these signaling molecules in vivo is 
incomplete.  
 
Knocking out Shp2 
Due to its pivotal developmental role, systemic Shp2 deletion results in early 
embryonic lethality123, 124; however, several cKO mouse models have been used 
to investigate the in utero requirement of Shp2 using various Cre drivers. These 
mouse models, although primarily embryonically lethal, have demonstrated Shp2 
can play a role in NC-mediated events such as cardiac outflow track 
development, septation of the ventricles of the heart, semilunar 
valvulogenesis125, craniofacial development, and Schwann cell-mediated 
myelination of the peripheral nervous system101, 126 as well as NC-independent 
events such as limb development127 and Ca2+ oscillations in cardiac 
fibroblasts128. Of particular relevance to the studies herein are the Shp2 cKO 
phenotype resulting from Nestin2-Cre30 and the Erk1/2 cKO phenotype driven by 
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Advillin-Cre101. Both Nestin2-Cre and Advillin-Cre are expressed in subsets of 
NC cells as well as the central nervous system and exhibit postnatal growth 
retardation, motility abnormalities, and death by approximately 3 weeks of age. 
 
Additional in vitro studies have shown that Shp2 is a key downstream factor in 
NGF signaling during sympathetic neuronal differentiation and subsequent 
neurite outgrowth86, 121, 122. However, the in vivo postnatal requirement of Shp2 
within NC lineages has remained unclear due to the predominance of 
embryonically lethal phenotypes observed in models of Shp2 loss in the NC. Our 
work focuses on addressing this gap in knowledge specifically regarding the role 
of Shp2 in development of sympathetic innervation of the heart. 
 
Role of Shp2 in myelination 
Shp2 signaling is critical for the migration and establishment of Schwann cells 
(SCs) and their precursors (SCPs) as well as the ability of those cells to 
effectively myelinate the peripheral nervous system. SCPs are derived from NC 
cells at approximately E12-13. SCPs then develop into immature SCs (E15-birth 
(E20)). Immature SCs adopt one of two fates postnatally: they either associate 
with a single large caliber axon and become myelinating SCs or they associate 
with many small caliber axons and become non-myelinating SCs as part of a 
Remak bundle129, 130 (Figure 4). Interestingly, SCs can dedifferentiate back to 
immature SCs and reenter the cell cycle before undergoing differentiation 
again131. The level of Neuregulin-1 (Nrg-1; a ligand for the EGFR family of 
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receptors) type III expressed by the axon appears to be, at least in in vitro 
models, an essential determinant of commitment to a myelinating phenotype130, 
132. This is achieved through promoting expression of the Schwann cell 
transcription factors Oct-6 and Krox-20101, 133. 
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Figure 4. Schematic of Schwann cell development. This schematic illustrates 
the progression of a NC cell to a SCP, immature SC, and eventually to a 
myelinating or non-myelinating SC. Developmental time points for presence of 
each of these stages are indicated in orange. Interestingly, differentiated SCs 
can dedifferentiate to immature SCs and then redifferentiate as either myelinating 
or non-myelinating SCs. This is particularly common after nerve injury when the 
SCs are no longer associated with a particular axon. Adapted from Mirsky et al., 
2002129. 
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Shp2 is required for Nrg-1 signal transduction through ERK which serves 
different functions at various developmental time points101, 126. When ERK1/2 or 
Shp2 are deleted early in NC development (E8.5) via Wnt1-Cre, no SCPs are 
present on the axons of peripheral nerves101, 126. This thought to be due to the 
fact that at this stage in development ERK1 and 2 are required to suppress 
myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) to prevent 
premature differentiation of glial cells101. In the absence of the suppressive effect 
of pERK1/2, it has been hypothesized that SCPs lose the ability to maintain their 
progenitor state which could explain their absence in ERK cKOs. There is also 
evidence that both MAPK and PI3K pathways must be simultaneously activated 
at E12 to prevent apoptosis in SCPs134. 
 
Interestingly, when ERK1/2 are deleted in SCPs using the Dhh-Cre (expressed at 
E13) or Shp2 is deleted using the Krox20-Cre (expressed E11-P4 depending on 
the lineage135), SCPs are present on peripheral axons, but they do not 
myelinate101, 126. These pups experience tremor and hindlimb paresis within 2 
weeks of birth. In the absence of an inducible Cre model or comparison with Cres 
expressed at different times but with a very similar expression pattern, we cannot 
conclusively determine the temporal requirements of Shp2 and ERKs; however, 
these studies indicate that Shp2 is required early in development for SCP 
survival and presence on the developing peripheral nerves and later in 
development for myelination. 
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It has been shown in vitro and in vivo that Shp2 mutation in SCs impaired 
sustained ERK1/2 signaling, but leaves PI3K/AKT activation unchanged126. This 
result reinforces the idea that certain branches of downstream Shp2 signaling are 
more important than others in various contexts. In in vitro culture, SCs lacking 
Shp2 did not proliferate or migrate in response to Nrg1 indicating that Shp2 
signaling through pERK is a key pathway essential for transducing Nrg1 signaling 
in SCs126. 
 
Role of Shp2 in neonatal cardiac innervation 
In the present study, we sought to explore the in vivo postnatal role of Shp2 and 
its downstream effectors within the development and maintenance of cardiac 
sympathetic innervation and neurocardiac coupling. We targeted Shp2 using a 
Periostin-Cre transgenic line (Figure 5) that uses a partial Periostin gene 
promoter to induce expression of Cre recombinase within post-migratory NC 
lineages136. The resulting phenotype in mice is one of failed sympathetic cardiac 
innervation and concomitant bradycardia. Molecular analysis indicated that 
downstream phosphorylated-extracellular signal-regulated kinase1/2 (pERK) was 
the primary signaling aberrancy within the sympathetic lineage. Further 
investigation revealed that genetic restoration of the pERK deficiency via lineage-
specific expression of constitutively active mitogen-activated protein kinase 
kinase-1 (caMEK1) was sufficient to rescue the sympathetic innervation deficit 
and its physiological consequences. These results demonstrate that Shp2 
signaling through pERK is required in vivo for the establishment of functional 
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sympathetic innervation within the postnatal heart. Moreover, these data provide 
a mechanistic basis for understanding the lineage-specific aspects of clinical 
presentations that can occur in diseases such as LS as well as other ECG 
abnormalities resulting from disturbed pERK-dependent sympathetic innervation. 
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Figure 5. Genetic schematic of Shp2 cKO. Genetic recombination in this 
model is driven by the Periostin-Cre generated in our lab. Essentially, in cells that 
activate the periostin promoter (mainly post-migratory NC cells), Cre 
recombinase is expressed. Cre then excises pieces of genomic DNA that are 
flanked by “LoxP” sites. In our model, all cells which express Cre delete exon 4 of 
Shp2 as well as the “stop” preceding the lacZ gene. Deletion of exon 4 of Shp2 
leads to absence of Shp2 protein expression while deletion of the “stop” allows 
for β–galactosidase expression from the lacZ gene. Because the presence of β–
galactosidase can be detected with staining, the ROSA promoter driving 
expression of the lacZ gene serves as our reporter system to identify all cells 
which express Cre or are derived from cells which expressed Cre. 
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MATERIALS AND METHODS 
 
Generation of mice 
Animal use was in accordance with institutional guidelines, and all experiments 
were reviewed and approved by the institutional Animal Care and Use 
Committee. Floxed Shp2 mice111 were obtained from G.S. Feng (Uni. of 
California San Diego) and intercrossed with Periostin-Cre [MGI:3775923] mice 
on a C57BL/6 background to generate lineage-restricted cKO offspring136 
containing a 3.9kb partial Periostin promoter that drives Cre expression within the 
NC-derived peripheral nervous system (including Schwann cells as well as 
sensory, enteric and sympathetic neurons)137. Initial cross was performed by 
Paige Snider, PhD. 
 
To facilitate lineage mapping, floxed Shp2;Periostin-Cre mice were intercrossed 
with β–galactosidase indicator mice21. In order to reconstitute pERK expression 
within the Shp2 cKO lineage, the floxed Shp2;Periostin-Cre mice were 
intercrossed with CAG-caMEK1 mice138 obtained from M. Krenz (Uni. Missouri-
Columbia) which were on a pure FVB/N background. The resulting ♂CAG-
caMEK1Periostin-Cre;Shp2f/+mice were bred to existing ♀Shp2f/f;R26r/R26r mice 
which yielded our desired compound mutant experimental genotype: CAG-
caMEK1;Periostin-Cre;Shp2f/f;R26r in the expected Mendelian ratio: 3:16. 
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To distinguish pups from littermates, their paws were tattooed in the first 5 days 
of life (Ketchum tattoo kit) to indicate a specific identity for each pup in the litter. 
This resulted in a permanent ID system with no morbidity noted. 
 
For weight and survival data, pups were monitored and weighed daily. After the 
initial observation was made that no pups survived past P20 and that weight loss 
preceded death, weight and gross appearance were carefully monitored as 
indicators of overall health. As indicated, pups were humanely euthanized prior to 
lethality. 
 
Genotyping mice lines 
The following primer sequences and PCR protocols were used for genotyping 
from tail clippings and verification of Cre-mediated recombination of floxed Shp2 
locus in isolated sympathetic trunk ganglia and brain DNA via PCR: For tail clip 
samples, DNA was isolated by Proteinase K digestion followed by ethanol 
precipitation and extraction. Samples were resuspended in 10mM TRIS-HCl pH 
8.5. 
 
For recombination studies, whole bodies of P2 pups were processed for β-
galactosidase staining. Following this procedure, sympathetic trunk ganglia (now 
easily visualized and separated from surrounding tissue) as well as brain tissue 
were collected. DNA isolation was carried out using the same method utilized for 
tail clip samples. 
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Periostin-Cre, sense 5’-ATGTTTAGCTGGCCCAAATG-3’, antisense 5’-
ACATGGTCCTGCTGGAGTTC-3’; PCR program: (1) 94 °C for 5 minutes, (2) 94 
°C for 1 minute, (3) 60 °C for 1 minute, (4) 72 °C for 1 minute, (5) go to (2) and 
repeat for 33 cycles, (6) 72 °C for 10 minutes. Amplified PCR product: 550 bp. 
Primers and PCR protocol designed by Paige Snider, PhD139. 
 
Shp2 flox, sense 5’-ATGGGAGGGACAGTGCAGTG-3’, antisense 5’-
ACGTCATGATCCGCTGTCAG-3’; PCR program: (1) 94 °C for 3 minutes, (2) 94 
°C for 30 seconds, (3) 57 °C for 30 seconds, (4) 72 °C for 1 minute, (5) go to (2) 
and repeat for 33 cycles, (6) 72 °C for 2 minutes. Amplified PCR product: wild-
type 300 bp; flox 400 bp111. 
 
Shp2 null, sense 5’-TAGGGAATGTGACAAGAAAGCAGTC-3’, antisense 5’-
AAGAGGAAATAGGAAGCATTGAGGA-3’; PCR program: (1) 94 °C for 5 
minutes, (2) 94 °C for 5 minutes, (3) 55 °C for 30 seconds, (4) 72 °C for 1 minute, 
(5) go to (2) and repeat for 40 cycles, (6) 72 °C for 5 minutes. Amplified PCR 
product: 350 bp111. 
 
CAG-caMEK1, sense 5’-TTGATCACAGCAATGCTAACTTTC-3’, antisense 5’-
GTACCAGCTCGGCGGAGACCAA-3’. PCR program: (1) 94 °C for 2 minutes, (2) 
94 °C for 30 seconds, (3) 54 °C for 30 seconds, (4) 72 °C for 30 seconds, (5) go 
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to (2) and repeat for 30 cycles, (6) 72 °C for 5 minutes. Amplified PCR product: 
460 bp. (Primers designed by Maike Krenz, PhD138). 
 
Ube1x (gender determination primers), sense 5’-
TGGTCTGGACCCAAACGCTGTCCACA-3’, antisense 5’- 
GGCAGCAGCCATCACATAATCCAGATG-3’. PCR program: (1) 94 °C for 1 
minute, (2) 98 °C for 15 seconds, (3) 66 °C for 20 seconds, (4) 72 °C for 1 
minute, (5) go to (2) and repeat for 34 cycles. Amplified PCR product: male 
samples give two bands (217 and 198 bp), female samples produce only one 
band (217 bp)140. 
 
R26r genotyping was as described21. ROSA, (1) 5’-
AAAGTCGCTCTGAGTTGTTAT-3’, (2) 5’-GCGAAGAGTTTGTCCTCAACC-3’, 
(3) 5’-GGAGCGGGAGAAATGGATATG-3’. PCR program: (1) 94 °C for 2 
minutes, (2) 94 °C for 30 seconds, (3) 58 °C for 1 minute, (4) 72 °C for 45 
seconds, (5) go to (2) and repeat for 33 cycles, (6) 72 °C for 5 minutes. Amplified 
PCR product: wild-type band 500 bp, mutant band 250 bp. 
 
Histologic analysis, lineage mapping, and molecular marker analysis 
Isolation of tissues, fixation, processing, and whole-mount staining for β-
galactosidase was performed as described141. Prior to molecular analysis, all 
harvested hearts were morphologically and histologically analyzed as 
described141. 
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Briefly, whole-mount β-galactosidase staining was achieved as follows: mouse 
pups ranging in age from E14.5-P20 were harvested (at least 3 age-matched 
littermate cKO and control at each age) and microdissected to enable efficient 
penetration of 4% paraformaldehyde fixative. Samples were fixed for 1.5 hours at 
4 °C. Samples were then rinsed in cold PBS (two rinses for 5 minutes each) 
followed by 4 rinses of 15 minutes each with β-gal buffer. After final rinse, 
samples were placed in fresh β-gal buffer and left rocking at 4 °C over night. If 
any residual blood was present in the wells the next morning, a final wash with β-
gal buffer was performed before addition of X-gal (substrate). After addition of X-
gal, samples were wrapped in foil and kept at 37 °C for 2-5 days.  
 
For whole-mount antibody analysis, following fixation overnight in 4% 
paraformaldehyde fixative at 4 °C, micro-dissected hearts were dehydrated at 
room temperature in increasing concentrations of methanol in 1% PBST, then 
bleached overnight at room temperature in a 3% H2O2 solution, rehydrated, 
blocked in 2% milk in PBST and DMSO, and then incubated in primary antibody 
(Tyrosine Hydroxylase; 1:1,000; Millipore) diluted in blocking solution for 3 days 
at 4 °C. The hearts were thoroughly rinsed in 1% PBST prior to secondary (goat 
anti-rabbit HRP; 1:200; Jackson Laboratories) application, then following a 3 day 
incubation at 4 °C were washed in 1% PBST overnight before being developed 
using DAB kit (Vector Laboratories). 
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For immunostaining slides were deparaffinized, rehydrated, and then processed 
using ABC kit (Vectorstain) as described23. The following primary antibodies were 
used: neuron-specific β3Tubulin (NSβT, 1:48,000; Abcam), tyrosine hydroxylase 
(TH, 1:10,000; Millipore), and TrkA (1:200; Millipore). Cell apoptosis was 
evaluated using TdT-FragELTM DNA Fragmentation Kit (Calbochem) following 
manufactures protocol. 
 
In situ hybridization of Hcn4, Phox2a, Phox2b, Gata3, Mash1 and Sox10 
(plasmids142 provided by P. Cserjesi, Columbia University) was performed by 
Jian Wang, MS on 10µm serial sections as described143 using sense and anti-
sense S35-labeled cRNA probes. 
 
For transmission electron microscopy (TEM), samples were isolated and fixed in 
2% paraformaldehyde, 2% gluteraldehyde fixative in 0.1M cacodylate buffer (pH 
7.2) overnight, processed by the EM core facility, and imaged on a Phillips400 
microscope (via IU EM Core) as described144. 
 
For all assays, serial sections were analyzed for at least 3 different mice of each 
genotype and at each developmental age. 
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Real-Time PCR and Western blot analysis 
Total RNA isolated from individual isolated P2, P7 and P14 hearts using the 
Direct-zolTM RNA MiniPrep kit (Zymo Research Corp.). This RNA was reverse-
transcribed and qPCR analysis of: 
 
Ngf (Left: TATACTGGCCGCAGTGAGGT; Right: 
GGACATTGCTATCTGTGTACGG), 
β1Adrenergic receptor (Left: CATCATGGGTGTGTTCACG; Right: 
GGAAAGCCTTCACCACGTT) 
Adenylate cyclase-6 (Left: GGGAGAAGGAGGAGATGGAG; Right: 
GGTCATAGGTGCTGGCATTT), and 
Hprt (Left: TGGCCCTCTGTGTGCTCAA; Right: 
TGATCATTACAGTAGCTCTTCAGTCTGA)  
 
mRNA expression levels were determined as described145. qPCR was carried out 
twice in duplicate (n=2). qPCR studies were done in collaboration with Emily 
Blue, PhD. 
 
Efficiency of Cre recombination induction for Shp2;Periostin-Cre and 
quantification of Shp2, pERK, pAKT and TH levels were measured by Western in 
isolated heart/ganglia region, adrenal gland, and brain samples at E14.5, P7, and 
P14 as described in145. Blots were probed with pERK (1:1,000;Cell Signaling); 
tERK (1:1,000;Cell Signaling); pAKT (1:1,000;Cell Signaling); tAKT (1:1,000;Cell 
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Signaling); Shp2 (1:1,000;Santa Cruz); TH (1:1,000;Millipore); and normalized to 
the housekeeping α-tubulin loading control (1:10,000;Sigma). Signal was 
detected via ECL-plus (Amersham) with peroxidase-conjugated goat anti-rabbit 
secondary antibody (1:5000; Promega). Densitometric quantification of Western 
data (n=4-6 samples per genotype/age) was analyzed using the AlphaVIEW SA 
program. 
 
Electrocardiograms 
Using Model F-E2 electrodes (Grass Technologies), ISO-Dam biological amplifier 
(World Precision Instruments, Inc), and a DAQCardA1-16XE-50 analog-to-digital 
converter (National Instruments), longitudinal ECG data were collected starting at 
P4 every other day until death. The mice were anesthetized with isoflurane (~30 
seconds for induction at 4 vol% at 2-liter oxygen flow and then maintained during 
ECG collection at 2% at 2-liter oxygen flow). Following induction, the mice were 
transferred onto a heat pad where 3 Model F-E2 electrodes (Grass 
Technologies) were inserted subcutaneously: where the right forelimb meets the 
trunk, where the left forelimb meets the trunk, and where the right hindlimb meets 
the trunk, respectively. Pilot studies done in collaboration with Michael Rubart, 
MD. Dr. Rubart graciously loaned me his ECG equipment to continue these 
studies. 
 
Isoflurane was chosen as the anesthetic due to its minimal cardiac depression146; 
however, slight cardiac depression is observed over time. The reproducibility of 
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the electrode placement does affect the amplitude of the ECG trace, but it does 
not alter time intervals (the parameter of interest). 
 
Data were acquired for ~5 mins, and then the mice were placed back with their 
mothers to recover. The pups recovered quickly (30 seconds to 1 minute) and 
resumed normal activity. Clampfit software was used for waveform analysis. 
ECG collection was done with and without isoproterenol (Sigma; i.p. 2µg/g of 
body weight147) and atropine (Sigma; 1.2µg/g148) challenge. For the atropine 
pharmacological studies, continuous ECG traces were collected for 25-30 
minutes after injection in order to document any heart rate alterations as 
atropine’s effects (if any are observed) peak at 20 minutes after injection148. 
 
Statistical analysis 
Densitometric analysis was examined for statistical significance using Student’s 
t-test. A P-value < 0.05 was regarded as significant. Error bars indicate standard 
error of the mean (SEM). Longitudinal heart rate data and isoproterenol 
challenge data were subjected to a two-way ANOVA followed by a Sidak’s test 
for multiple comparisons. Heart rate data for the three genotypes were tested for 
significance with a one-way ANOVA followed by Tukey’s multiple comparisons 
test. All statistical tests were performed using GraphPad Prism 6 statistical 
software.  
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RESULTS 
 
Establishment of Shp2 cKO mouse line 
Conditional Shp2 floxed mice containing a floxed exon 4111 were intercrossed 
with Periostin-Cre transgenic mice to generate embryos that were deficient for 
Shp2 protein within many post-migratory NC lineages from embryonic day (E) 10 
onward. Periostin-Cre mice express Cre under the control of a partial 3.9kb 
Periostin promoter (as demonstrated by R26r indicator mice21) within the 
peripheral nervous system (including autonomic, sensory, enteric nervous 
systems as well as glial components such as Schwann cells). Cre is also 
expressed in the pharyngeal arches, outflow tract of the heart, adrenal glands, 
endocardial cushion lineages and future valves, but is absent from the central 
nervous system (brain and spinal cord) as indicated by lineage mapping for all 
stages investigated136, 137 (Figure 6). Periostin-Cre is also expressed in fetal and 
neonatal cardiac fibroblasts which are non-NC derived structures 149 but is 
absent from in utero and postnatal cardiomyocytes149-151. 
 
Homozygous Shp2 cKO newborns were genotyped via PCR at expected 
Mendelian inheritance ratios (n=11 litters) and lineage mapping utilizing the R26r 
reporter21 confirmed Cre-mediated recombination in a pattern suggestive of post-
migratory NC lineages beginning at E10 with extensive recombination observable 
by E11.5 (Figure 6). This result demonstrated that our conditional gene-targeting 
strategy did disrupt normal Shp2 expression in utero but did not cause any gross 
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embryonic defects and circumvented the in utero lethality observed within other 
NC-restricted models of Shp2 ablation103, 123.  
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Figure 6. Lineage mapping of Periostin-Cre expression via β-galactosidase 
staining. Lineage mapping of Periostin-Cre expression via β-galactosidase 
staining of E11.5 embryo (A), E16 embryo (B,C) and P2 pup (D,E) demonstrated 
Cre expression pattern suggestive of post-migratory NC lineages including the 
craniofacial region, dorsal root ganglia, sympathetic trunk (* in A,B,E), enteric 
ganglia, and peripheral nerves including those innervating the heart (A-D; arrows 
in C). [Paige Snider, PhD is responsible for carrying out the initial cross to 
generate Shp2 cKOs and provided the images for panels A-C]. (Figure adapted 
from Lajiness et al., 2014). 
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Validation of molecular model 
Lineage-specific recombination was verified in DNA isolated from mutant 
sympathetic trunk ganglia (Cre-expressing) but not brain (Cre-negative as 
indicated by lacZ expression for all ages of interest in this study) (Figure 7A). 
Deletion of exon 4 of Shp2 resulted in decreased Shp2 protein levels in 
microdissected partial heart/cardiac ganglia samples (Figure 7B) and NC-
containing adrenals (Figure 8). These tissues were chosen as they are enriched 
for Periostin-Cre-expressing cells (see Figure 6); however, it is important to 
remember that neither the partial heart/cardiac ganglia nor adrenal gland is 
entirely Cre positive so it is unlikely ubiquitous Shp2 would be completely 
eliminated in these samples. 
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Figure 7. Molecular verification of model. (A) PCR analysis of recombination 
efficiency demonstrating the lineage-specific nature of Shp2 knock out. 
Recombination efficiency was calculated via densitometry to be 78.8% within 
cKO ganglia (*). (B) Composite Western blot of heart and brain isolates 
confirming the lineage-specific nature of Shp2 cKO at the protein level. Shp2 
levels were decreased in heart (*) but not brain isolates both in utero and 
postnatally. (Figure adapted from Lajiness et al., 2014). 
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Figure 8. Shp2 and pERK levels are levels are decreased in NC-containing 
adrenal glands. (A, B) Whole-mount β-galactosidase staining of a Periostin-Cre 
expression in control (A) and mutant (B) P7 adrenal glands illustrating Cre-
positive adrenal medulla (*) and Cre-negative cortex (c). (C) Composite Western 
blot illustrating decreased pERK and Shp2 protein levels in whole adrenal 
isolates, when normalized to total ERK levels (n=3). (Figure from Lajiness et al., 
2014). 
  
50 
 
Shp2 cKOs are indistinguishable from control littermates at birth 
Shp2 cKOs were indistinguishable from littermate controls at birth but by the 2nd 
week of life, the mutants exhibited diminished growth, and none survived past 
postnatal (P) day 21 (Figure 9). The initial lethality phenotype was found by 
Paige Snider, PhD and Rachel Young. Since a previously reported Shp2 cKO 
model using Nestin-Cre exhibited an earlier and more severe phenotype in 
males30, we used PCR analysis (using Zfy sex determination primers140) to 
determine gender of all neonatal mutants. However, we did not detect any sex-
related bias in our model (n=24 cKOs; Figure 10). 
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Figure 9. Growth and survival of Shp2 cKOs. (A,B) Control and mutant (*) 
pups at P2 (A) and P9 (B) (mutants indicated by asterisk). (C) Longitudinal 
growth curve compiled from 7 litters. (D) Survival curve (n=24 cKOs). Error bars 
indicate SEM. (Panel A adapted from Lajiness et al., 2014). 
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Figure 10. Survival curve of mutants separated by gender. Percent survival 
of male and female Shp2 cKOs over time (n=12). 
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Necropsy verified normal craniofacial (Figure 11) and cardiovascular 
development. Similarly, histology and R26r reporter analysis revealed that 
despite Cre expression within the embryonic outflow tract and valves, both 
outflow tract morphogenesis and valvular maturation were unaffected (Figure 
12). However, diminished peripheral and enteric innervation were noted (Figure 
13) and are thought to contribute to the failure to thrive and lethality observed in 
Shp2 cKOs. 
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Figure 11. Shp2 cKOs do not exhibit gross craniofacial malformations. 
Gross image of P9 control (A) and mutant (B) hard and soft palates illustrating 
that no clefting or other gross defects are present (n=3). 
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Figure 12. Shp2 cKO outflow tract and valves are normal. (A-D) Hematoxylin 
and eosin histological staining of transverse sections through the outflow vessels 
(A,B) and valvular planes (C,D) of E14.5 wild-type (+/+) and cKO outflow tracts. 
Note that both are normally septated and that the orientation of the separate 
aorta (Ao) and pulmonary (p) trunks is similar. Additionally, the aortic and 
pulmonary valve leaflets are positioned appropriately and of similar thickness. 
(E,F) Histology of E16.5 wild-type and cKO fully formed aortic valves reveals 
comparable maturation. (G-J) Lineage mapping of Periostin-Cre expression via 
β-galactosidase staining and eosin counterstaining in histological sections 
revealed morphologically normal aortic/pulmonic (G,H) and mitral/tricuspid (I,J) 
valves in both the P14 mutant and littermate control despite Cre expression from 
E10 onward. (K,L) Similarly, histology demonstrated normal architecture of 
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vascular smooth muscle cells within the myocardium of P14 Shp2 cKOs. Scale 
bar in A-F and G-L is 50µm. (Figure adapted from Lajiness et al., 2014).
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Figure 13. Shp2 cKO enteric and peripheral nervous systems are 
diminished. (A,B) Postnatal day 7 guts were immunostained with neuron 
specific β3 tubulin (NSβT) antibody to detect the enteric nervous system 
embedded in the lining of the gastrointestinal tract. Note that the cKOs exhibit 
diminished enteric innervation (B) compared to wild-type control littermate (A). 
Insets are whole-mount R26r lineage mapping of Periostin-Cre in wild-type and 
cKO P7 GIs, verifying a paucity of enteric NC within the cKO GI. (C,D) Similarly, 
whole-mount β-galactosidase staining of control (C) and mutant (D) ribcages 
revealing diminished peripheral innervation in cKOs compared to littermate 
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controls. Thus, the observed failure to thrive and subsequent lethality observed in 
this model is most likely multifactorial, and in conjunction with the diminished 
sympathetic cardiac innervation and concomitant bradycardia, the diminished 
peripheral and enteric innervation are most likely contributing factors to the 
eventual lethality observed. (Figure adapted from Lajiness et al., 2014). 
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Shp2 cKOs exhibit abnormal peripheral innervation 
To further investigate the diminished peripheral innervation observed and 
determine its relationship to the failure to thrive phenotype, the pups were 
observed for behavioral abnormalities and necropsies were performed 
immediately after death or at time of harvest. Necropsies often revealed present 
but decreased milk in the digestive tract of mutants as early as P6 in severe 
cases. This was frequently accompanied by air in the bowel. Culling littermates to 
reduce litter size did not affect mutant longevity nor necropsy results which 
indicate that mutant pups not only have trouble outcompeting littermates for food, 
but may also have difficulty ingesting food regardless of competition. Since 
peripheral innervation was suspected to be less robust due to the lineage 
mapping results (see Figure 13), innervation of the tongue was examined in 
mutants and controls via immunohistochemistry. This preliminary study revealed 
diminished overall innervation (both motor and sensory) to the tongue which may 
contribute to the failure of pups to access food (Figure 14).  
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Figure 14. Abnormal innervation observed in Shp2 cKOs. (A) H&E stained 
section of a P6 control tongue. (B) NSβT IHC of an adjacent slide. (C) H&E 
stained section of a P6 mutant tongue. (D) NSβT IHC of an adjacent slide. Notice 
the lack of innervation in the Shp2 cKO tongue (n=2). As NSβT is a generic 
neuronal marker this study indicates an overall paucity of innervation. The 
innervation of the tongue includes sensory innervation which is a branch of the 
trigeminal nerve (cranial nerve V) for the anterior 2/3rds of the tongue and the 
glossopharyngeal nerve (cranial nerve IX) in the posterior 1/3rd; motor which is 
from the hypoglossal nerve (cranial nerve XII); and taste (gustatory neurons 
innervating the taste buds) which is from the facial nerve (cranial nerve VII) in the 
anterior 2/3rds of the tongue and the glossopharyngeal in the posterior 1/3rd of the 
tongue152. The complexity of the innervation present in the tongue makes 
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delineating specific contributions with NSβT IHC impossible, but the overall 
diminished innervation indicates that there are, most likely, deficiencies in 
multiple sources of innervation.  
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Postnatally, Shp2 cKOs exhibit diminished neurite outgrowth from cardiac 
sympathetic ganglia 
To investigate the NC-specific effects of Shp2 KO in post-migratory NC lineages, 
we carried out lineage mapping using the lacZ reporter system21. The largest 
collection of the heart’s sympathetic innervation is located on the dorsal surface 
of the heart, and there we observed significantly diminished neurite outgrowth 
from cKO TH-positive cardiac ganglia at both P2 and P14 (Figure 15). Whole-
mount spatiotemporal analysis of β–galactosidase expression revealed that 
cardiac sympathetic ganglia in Shp2 cKO mice have fewer projections and that 
the neurites that are present are less robust (Figure 15A,B,G,H) than those 
observed in age-matched littermate controls (Figure 15D,E,J,K). In the Shp2 cKO 
mice the ganglia themselves, however, do not appear grossly atrophic or 
morphologically compromised. Detailed histology revealed typical neuronal 
architecture, namely, large dense nucleus with wavy axonal projections 
emanating from both the control (Figure 15 F,L) as well as the ganglia in the 
Shp2 cKOs (Figure 15C,I). 
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Figure 15. Shp2 cKOs exhibit diminished neurite outgrowth from cardiac 
ganglia. (A-C) P2 Shp2 cKO cardiac ganglia (arrows): whole-mount β-
galactosidase staining (A), black and white reconstruction trace of surface neurite 
outgrowth (B), and histological section of β-galactosidase stained ganglia 
counterstained with eosin (C). (D-F) Same sequence of littermate P2 control. (G-
L) Same sequence of P14 mutant (G-I) and littermate P14 control (J-L). Note 
both P2 and P14 cKOs exhibit reduced neurite outgrowth. Scale bar in A is 
100m and also applies to images in D,G, and J; scale bar in C is 20m and also 
applies to the images in F,I, and L. (Figure adapted from Lajiness et al., 2014).  
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Decreased sympathetic innervation is observed in Shp2 cKO hearts 
In light of the decreased neurite outgrowth despite the normal gross anatomical 
appearance of the ganglia, molecular characterization of Shp2 cKO cardiac 
ganglia utilizing immunohistochemistry techniques was conducted. Despite the in 
utero loss of Shp2, the ganglia of E14.5 Shp2 cKOs consistently express neuron-
specific NSβT, TrkA (the high-affinity receptor of NGF, required for sympathetic 
neuron survival) and the sympathetic neuronal marker TH (Figure 16A-C). A 
similar pattern was observed in the ganglia of the E16.5 Shp2 cKOs (Figure 17). 
However, postnatally the expression of TH in ganglia from Shp2 cKOs is 
diminished at all ages investigated (P7 (Figure 16F); P0, P6, P18 (Figure 17)) 
while NSβT and TrkA remain unaltered (Figure 16D,E). Moreover, the ganglia in 
postnatal Shp2 cKOs are similar in size and cellularity to ganglia in controls, and 
TUNEL staining did not detect any apoptotic cells (Figure 16G). 
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Figure 16. Shp2 cKOs demonstrate diminished cardiac sympathetic 
innervation. (A-C) Immunohistochemistry (IHC) demonstrating equivalent NSβT 
(A), the NGF receptor TrkA (B), and TH (C) expression in E14.5 littermate pairs 
of controls (top) and mutant (bottom)ganglia. (D-G) Adjacent sections of P7 
ganglia (control, top panel; mutant: lower panel) examined using IHC NSβT (D), 
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TrkA (E), TH (F), and apoptosis (TUNEL; G). Note that P7 Shp2 cKO ganglia 
exhibited diminished TH expression but are not apoptotic. However, apoptotic 
cells are seen in adjacent tissue (arrow in cKO G; n=3 littermate pairs with 2 
slides containing 4-5 sections of tissue each analyzed). (H,I) IHC detection of 
TH-positive nerves on the left ventricle of a P0 control (H) and mutant (I). (J,K) 
TH IHC of P7 ventricle of a control (J) and mutant (K). Note the lack of 
sympathetic innervation in the mutant heart at both ages, but normal surface 
(arrows, H) and penetrating (J) TH-positive nerves around blood vessel (v) in 
wild-types. (L) Densitometry quantification of TH protein levels as detected by 
Western within isolated P14 hearts (n=5). Shp2 cKO TH levels relative to loading 
control (α-tubulin) were significantly decreased (t-test; p-value=0.0010). Error 
bars represent SEM. (Figure adapted from Lajiness et al., 2014).  
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Figure 17. Temporal analysis of TH expression within cardiac ganglia and 
during cardiac innervation. Longitudinal sympathetic innervation of Shp2 
cKOs. (A,B) TH IHC detection of cardiac ganglia (upper panels) and sympathetic 
innervation of the ventricles (indicated via arrows in lower panels) of E16.5 
hearts. Note both control (A) and cKO (B) cardiac ganglia appear to have normal 
TH expression, but there is diminished sympathetic innervation in the ventricle of 
the Shp2 cKO. (C,D) P0 cKO cardiac ganglia (C) exhibit diminished TH 
expression compared to control (D), and there is decreased sympathetic cardiac 
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innervation evident in the Shp2 cKO ventricles. (E,F) TH expression is 
diminished within P6 cKO cardiac ganglia and there is reduced sympathetic 
innervation (F) compared to wild-type littermate control (E). (G,H) TH IHC of 
cardiac ganglia and ventricle of a control (G) and mutant (H) at age P18. Note, 
that although the Shp2 cKO ganglia are similar in size to controls, that the mutant 
ganglia have decreased TH expression only during postnatal stages. However, 
the mutant ventricles exhibit diminished TH-marked innervation at all ages 
examined. Scales bar in all upper panels is 20µm, A-D lower panels is 50µm and 
E-H lower panels is 100µm. (Figure adapted from Lajiness et al., 2014). 
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Significantly, global cardiac sympathetic innervation of the Shp2 cKO was 
compromised. At day 0, nodules of TH-positive innervation is observed in control 
(arrows; Figure 16H) but not in Shp2 cKO hearts (Figure 16I) and by P7 the 
mutant has substantially decreased TH-positive innervation (Figure 16J, K), 
particularly around the blood vessels supplying the ventricles (where sympathetic 
innervation is most pronounced in the control). Diminished TH-positive 
innervation was also observed in E16.5, P6, and P18 Shp2 cKO hearts (Figure 
17). Interestingly, despite diminished global cardiac sympathetic innervation, the 
epicardial-to-endocardial gradient was present in both controls and Shp2 cKOs 
(Figure 18).To further validate diminished TH expression in the heart of Shp2 
cKOs, Western analysis performed on microdissected heart/ganglia regions 
confirmed that TH levels were decreased by 70% in Shp2 cKO hearts versus 
hearts of control littermates (Figure 16L). 
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Figure 18. Although sympathetic innervation is globally decreased in cKOs, 
the epicardial-to-endocardial innervation gradient is preserved. (A,B) 
Tyrosine hydroxylase IHC of P18 littermate control showing sympathetic 
innervation surrounding a blood vessel in the subepicardial (A) as well as the 
subendocardial (B) region of the myocardium. (C,D) TH IHC of P18 cKO showing 
sympathetic innervation surrounding a blood vessel in the subepicardial (C) as 
well as the subendocardial (D) region of the myocardium. Note that there is less 
pronounced sympathetic innervation in the endocardial region of both control and 
Shp2 cKO hearts when compared to their respective epicardial region (n=4-5 of 
each genotype). (Figure adapted from Lajiness et al., 2014). 
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Radioactive in situ hybridization was used to examine whether the ganglia of 
Shp2 cKOs aberrantly express markers of early embryonic sympathetic neuronal 
differentiation. Both Phox2a and Phox2b mRNA were expressed in Shp2 cKO 
but not control ganglia (Figure 19). Additional embryonically expressed 
sympathetic neuronal differentiation factors (Gata3, Sox10, and Mash1) were 
also investigated but found to be negative in both controls and mutants. In situ 
hybridization studies performed by Jian Wang, MS. 
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Figure 19. Postnatal Shp2 cKOs aberrantly express the embryonic 
sympathetic neuronal differentiation markers Phox2a and Phox2b. (A,B) In 
situ hybridization of mutant cardiac ganglia showing aberrant expression of 
Phox2a (embryonic sympathetic neuronal differentiation marker; A) in the context 
of diminished TH expression (B). (C,D) In situ hybridization of mutant cardiac 
ganglia showing aberrant expression of Phox2b (embryonic sympathetic 
neuronal differentiation marker; C). Lower panel is a phase contrast image of the 
ganglia itself (D). (E,F) Representative in situ hybridization of control cardiac 
ganglia showing no expression of Phox2b (E). Lower panel is a phase contrast 
image of the ganglia (F). [Radioactive in situ data provided by Jian Wang]. 
(Figure adapted from Lajiness et al., 2014).  
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Shp2 cKOs experience sinus bradycardia 
To investigate whether the observed Shp2-dependent innervation defect has any 
functional impact, longitudinal ECG analysis was carried out from P4 to P20, with 
readings taken every other day. These studies revealed that the Shp2 cKOs 
exhibit sinus bradycardia (slow heart rate with normal P-wave present; two-way 
ANOVA, P=0.0012; Figure 20A,B) beginning at P12, corresponding to the 
developmental timing of sympathetic control of heart rate53, 77. At P6, before the 
sympathetic nervous system is thought to be functionally relevant for establishing 
basal heart rate, there is no difference in heart rate between Shp2 cKOs and 
littermate controls (Figure 20A,B). However, by P12 the heart rate of the control 
pups significantly increased (the increase is associated with establishment of 
sympathetic control of heart rate) while the heart rate of Shp2 cKOs did not show 
a corresponding increase (Figure 20A,B). There was no increase in the average 
heart rate of the control littermates from P12 to P17 (average heart rate of 501 
and 506 bpm respectively). Similarly, there was no appreciable change in the 
average heart rate of Shp2 cKOs between P12 and P17 although there was a 
slight trend toward decreasing heart rates over time (average heart rates of 460 
and 414 respectively) (Figure 20A,B). 
  
74 
 
 
Figure 20. Shp2 mutants exhibit progressive sinus bradycardia. (A) 
Characteristic ECG traces from a wild-type littermate control and a Shp2 cKO at 
three different ages (P6, before sympathetic innervation is functionally relevant to 
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heart rate; P12, once sympathetic innervation is functionally established; and 
P17, demonstrating the continual decline of heart rate as the phenotype 
progresses) are shown. (B) Graphic representation of average heart rates 
collected at the three ages in (A). The heart rate of control animals increased 
over time from P6 to P12 and then plateaued while the Shp2 cKO heart rate 
never significantly changed (2-way ANOVA, Sidak’s multiple comparisons 
Control: P6vsP12 p<0.05, P6vsP17p<0.05, P12vs17=non-significant (p>0.05) 
Shp2 cKO: none of the comparisons of any of the different time points were 
significant; Control vs. Shp2 cKO at a single time point: P6 non-significant, P12 
p<0.05, P17 p<0.05 (n=7-19)). Error bars represent SEM. (Figure adapted from 
Lajiness et al., 2014). 
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No other arrhythmias or anomalies in the ECG wave form (P-wave duration, PR, 
or QRS intervals) were observed throughout the study with the exception of a 
mild prolongation of the PR interval immediately preceding death (Table 1). 
However the first degree heart block (the clinical name for prolonged PR interval) 
never progressed to second degree heart block or initiated any arrhythmias. 
Furthermore, this finding may be complicated by other issues such as the weight 
loss that was observed in the final 24 hours of life. QT intervals were also 
examined, but the absence of a definitive T wave in many traces negated the 
utility of such an investigation. 
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Table 1. Longitudinal ECG functional data. Other than sinus bradycardia, no 
anomalies in the ECG wave form of Shp2 cKOs were observed. Table 1 includes 
heart rate (HR, beats per minute), P-wave duration (in milliseconds), PR interval 
(in milliseconds), and QRS interval (in milliseconds) data collected from control 
and Shp2 cKO littermates longitudinally (n=7-19). Bolded entries indicate 
significant differences (p-value<0.05) between control and Shp2 cKO values at 
that time point. (Table from Lajiness et al., 2014).
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To examine the underlying cause of the sinus bradycardia, several 
pharmacological interventions were employed. Due to the diminished 
sympathetic innervation observed in the cKO heart (see Figures 16 and 17) we 
hypothesized that the lack of adrenergic stimulation was directly responsible for 
the observed phenotype. To test this hypothesis, we directly activated the β-
adrenergic receptors (the receptors that would normally be stimulated by 
sympathetic neuron release of norepinephrine) by administering an i.p. injection 
of the β1- and β2-adrenoreceptor agonist, isoproterenol. Isoproterenol increased 
the heart rate in both the control and Shp2 cKOs by 30% with respect to their 
basal heart rates (Figure 21). Moreover, the relative increase is consistent with 
the results reported from isoproterenol challenge tests carried out in adult mice147 
and confirms that the Shp2 cKO cardiomyocytes are capable of responding to 
adrenergic stimulation. In contrast, inhibiting parasympathetic activity with 
atropine had no significant effect on the heart rate of either Shp2 cKO or 
littermate controls (Figure 22). This was not particularly surprising due to the fact 
that the parasympathetic influence on murine heart rate is often minimal and 
subject to change on differing genetic backgrounds153, 154. 
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Figure 21. Isoproterenol increases heart rate in both control and Shp2 
cKOs. Graphic representation of heart rate increase (normalized to basal heart 
rate, indicated by dotted line) following i.p. injection of isoproterenol (2mg/kg 
body weight). Both mutant and control heart rates increased with isoproterenol 
administration (paired t-test; p=0.003); however, the genotype of the animal did 
not affect the degree to which the heart rate was elevated (2-way ANOVA 
interaction (genotype x treatment): p=0.905, (n=4-6)). Error bars represent SEM. 
(Figure adapted from Lajiness et al., 2014). 
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Figure 22. Shp2 cKO parasympathetic activity is unaffected. Line graph 
depicting the longitudinal effect of atropine. The slight cardiodepressive trend 
over time is due to prolonged exposure to isoflurane as indicated by the “No 
Atropine” control. The effects of atropine are negligible in both the control and 
mutant indicating that elevated parasympathetic tone is not responsible for the 
slower heart rate in mutants (n=2-3 for each condition and genotype). (Figure 
adapted from Lajiness et al., 2014). 
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To exclude the possibility that the β-adrenergic receptors or their downstream 
signaling effectors were misexpressed in Shp2 cKOs, qPCR was used to 
measure the levels of mRNAs encoding the β1-adrenergic receptor (the primary 
adrenergic receptor expressed in the heart) as well as adenylate cyclase-6 (the 
enzyme that produces cAMP as a second messenger to propagate the 
adrenergic signal). Levels of both targets were found to be equally expressed in 
the hearts of P14 Shp2 cKO as well as littermate controls (Figure 23). This result 
corroborates findings reported in other models of NGF signaling alterations155. 
Furthermore, heart Ngf levels, (as quantified via qPCR) were found to be the 
same between Shp2 cKOs and controls for all ages investigated (Figure 24). This 
was expected as regulation of NGF synthesis throughout development is 
independent of sympathetic innervation or norepinephrine secretion at the target 
organ156. Taken together, these data suggest that the diminished cardiac 
innervation does not affect the induction of neurotrophic factors within the heart. 
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Figure 23. Shp2 cKO hearts exhibit normal expression of β1-adrenergic 
receptor and adenylate cyclase-6 mRNA. (A) qPCR analysis of β1-adrenergic 
receptor (β1AR) mRNA levels normalized to Hprt cDNA synthesis and loading 
control, within P14 control and Shp2 cKO isolated hearts demonstrating 
equivalent expression levels (n=2). (B) qPCR analysis of adenylate cyclase-6 
(A/C6) mRNA levels normalized to Hprt housekeeping control. Note that although 
A/C6 expression levels are lower than β1AR, they are also similar in control and 
Shp2 cKO isolated P14 hearts (n=2). Error bars represent SEM. [qPCR 
experiments done in collaboration with Emily Blue, PhD]. (Figure adapted from 
Lajiness et al., 2014). 
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Figure 24. NGF expression is unaltered in Shp2 cKOs. qPCR analysis 
illustrating comparable levels of Ngf between control and Shp2 cKO hearts 
throughout the first 2 weeks of life. Error bars represent SEM. [qPCR 
experiments done in collaboration with Emily Blue, PhD]. (Figure adapted from 
Lajiness et al., 2014). 
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To rule out any potential abnormalities in the SA node as a possible contributing 
factor to the sinus bradycardia observed, Hcn4 expression was examined. HCN4 
is a key channel located primarily in the SA node that helps maintain a regular 
heart rhythm. Significantly, no disparities between Hcn4 expression levels or 
localization were detected between control and Shp2 cKO SA nodes (Figure 25). 
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Figure 25. Shp2 cKOs exhibit normal SA node structure and expression of 
Hcn4. In situ hybridization analysis of Hcn4 expression in wild-type (A,C) and 
Shp2 cKO (B,D) P7 hearts. Hcn4 was similarly present in both control and Shp2 
cKO SA nodes (arrows in A,B), the wall of the right atria (arrows in C,D) and on 
top of the ventricular septums (arrowheads in C,D).Abbreviations: ra, right atria; 
svc, superior vena cava; vs, ventricular septum. [Jian Wang performed the 
radioactive in situ hybridization shown]. (Figure adapted from Lajiness et al., 
2014). 
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Also, as Periostin-Cre is expressed in cardiac fibroblasts which are responsible 
for insulating the intrinsic conduction system of the heart, lacZ-positive fibroblasts 
were quantified and found to be comparable between mutants and controls at all 
ages investigated (Figure 26A,B). Additionally, the levels of αSmooth muscle 
actin (a marker expressed by cardiac fibroblasts, particularly early in 
development) was equitable (Figure 26C), indicating that cKO cardiac fibroblasts 
are present, appropriately localized, and express normal markers. 
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Figure 26. LacZ-positive cardiac fibroblasts are similar in number, 
localization, and expression patterns between Shp2 cKOs and controls. 
(A,B) Lineage mapping of Periostin-Cre expression via β-galactosidase staining 
and eosin counterstaining in histological sections revealed normal distribution 
and number of cardiac fibroblasts in both P14 controls and Shp2 cKOs. (B) 
Quantification revealed that the relative proportion of LacZ-positive cardiac 
fibroblasts observed in atria at three different ages of control/Shp2 cKO pairs is 
comparable in wild-types and Shp2 cKOs (n=2-3). (C) Composite Western blot 
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confirming equivalent expression of α-smooth muscle actin in control and mutant 
isolated P14 ventricles (n=4 pooled samples). Error bars represent SEM. 
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Although histology did not reveal any structural abnormalities, the microstructure 
of the control and Shp2 cKO ventricular myocardium were further investigated via 
electron microscopy. Similar to the results obtained in the histological analysis, 
lineage mapping, and qPCR data presented earlier, the contractile apparatus and 
mitochondrial architecture did not differ between Shp2 cKOs and littermate 
controls (Figure 27). These data indicate that Periostin-Cre mediated lineage-
restricted loss of Shp2 does not adversely affect the Shp2 cKO heart itself. 
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Figure 27. Shp2 cKO hearts are structurally normal. Electron microscopy 
examination of control and mutant myocardium revealed normal contractile 
apparatus and mitochondrial (m) architecture in the P14 Shp2 cKO and control 
hearts. Scale bar is 500nm. [IU EM core processed the heart tissue and collected 
the images shown]. (Figure adapted from Lajiness et al., 2014). 
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Decreased pERK is a primary signaling abnormality observed in Shp2 
cKOs 
Shp2 is an important factor in several signaling cascades, particularly in the 
modulation of the MAPK signaling cascades110. Published data have shown that 
cKO of Shp2 within pre-migratory NC results in diminished pERK signaling and 
that transient ERK1/2 activation is necessary for expression of smooth muscle 
and neural markers in NC in vitro123. Similarly, Shp2-deficent hematopoietic stem 
and progenitor cells show defective ERK and AKT activation157. In contrast, Shp2 
impaired cardiomyoctes exhibit increased levels of phosphorylated AKT 
(pAKT)158-160. As they are the two major postnatal effector molecules studied in 
models of Shp2 dysregulation, we examined pERK and pAKT levels. Western 
analysis of microdissected heart/cardiac ganglia protein isolates (containing only 
the top of the hearts that are enriched for Cre-postive cells) revealed that pERK 
protein levels were decreased in Shp2 cKOs by 50% at both E14.5 as well as P7 
(Figure 28A,B). However, in the Shp2 cKOs pAKT levels were unaltered both in 
utero and postnatally (Figure 28A,C). These results indicate that the ERK1/2 
branch of the MAPK pathway as opposed to the AKT pathway is selectively 
affected in the Shp2;Periostin-Cre mutants and suggest that Shp2 activity in the 
post-migratory NC is essential for pERK-mediated differentiation and 
establishment of cardiac sympathetic neurons but not their survival which is 
dependent on AKT signaling. 
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Figure 28. Shp2 cKOs exhibit a decrease in cardiac pERK signaling both 
embryonically and postnatally while pAKT signaling remains unaltered. (A) 
Representative composite Western blot illustrating decreased pERK levels in 
mutant microdissected heart/cardiac ganglia (*) compared to wild-type at both 
E14.5 and P7, but equivalent total ERK levels (n=5). However, Shp2 cKO pAKT 
levels were unaltered at these ages (n=3). (B) Densitometric quantification of 
pERK to tERK ratios at E14.5 and P7 (t-test, *p-value<0.05 (E14.5 p-
value=0.0052; P7 p-value= 0.0008)). (C) Densitometric quantification of pAKT to 
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tAKT ratios (t-test, p-value=0.498 (E14.5); p-value=0.758 (P7)). Error bars 
represent SEM. The significant reduction pERK levels suggests a 
disproportionate amount of the active pERK signaling in our neonatal 
microdissected heart/cardiac ganglia samples was within the NC/Periostin-Cre-
positive lineage. Moreover, unlike both total ERK1,2 and Shp2 which are 
ubiquitously expressed, pERK levels are known to fluctuate within a dynamic 
spatiotemporal tissue-restricted pattern in both mouse161 and human tissues162. 
(Figure adapted from Lajiness et al., 2014). 
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Genetic restoration of pERK signaling rescues the cardiac innervation 
phenotype of Shp2 cKOs 
We next determined whether diminished pERK levels were directly responsible 
for the sympathetic innervation phenotype observed in Shp2 cKOs. To reactivate 
ERK1/2 signaling, a conditional floxed-stop model of caMEK1 (the effector 
directly upstream of ERK) was crossed onto the Shp2;Periostin-Cre background 
(Figure 29A). In this way, any cell expressing Cre will simultaneously delete Shp2 
and express caMEK1138 in a lineage-restricted manner. The Shp2;Periostin-
Cre;caMEK mice had significantly higher pERK levels than their non-caMEK1 
expressing mutant littermates, and importantly, in the Shp2;Periostin-Cre;caMEK 
mice, pERK levels were comparable to wild-type age-matched littermate controls 
(Figure 29B). Shp2;Periostin-Cre;caMEK TH levels were similarly restored to 
wild-type levels (Figure 29C).  
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Figure 29. Schematic of genetic rescue and molecular characterization of 
resulting mice. (A) Schematic of caMEK1 genetic construct. (B) Western 
analysis of P14 heart isolates demonstrated that pERK levels in a rescued 
mutant (cKO + caMEK1) are similar to those in wild-type littermates, while pERK 
in a Shp2 cKO is still drastically decreased. (C) Western analysis of heart 
isolates demonstrated TH levels are also normalized in a rescued mutant and are 
similar to a wild-type littermate, but TH levels relative to α-tubulin loading control 
are still drastically decreased in Shp2 cKO hearts. (Figure adapted from Lajiness 
et al., 2014). 
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Moreover, immunohistochemistry revealed restoration of TH expression 
throughout the Shp2;Periostin-Cre;caMEK cardiac ganglia (Figure 30A-C) as well 
as an increase in TH-positive innervation properly localized around the blood 
vessels in the myocardium of the caMEK1 expressing cKO ventricle (Figure 30D-
F). The restored sympathetic innervation on the dorsal surface of the P14 
Shp2;Periostin-Cre;caMEK heart was verified via whole-mount TH-
immunostaining. The latter analysis revealed substantially increased arborization 
in the “rescued” mutant as compared to the non-rescued Shp2;Periostin-Cre 
mutant (Figure 30G-I). Consequently, the heart rates of Shp2;Periostin-
Cre;caMEK rescued mutants were normalized to control levels at all ages 
investigated (P14 shown; Figure 31). Thus, the rescue of sympathetic innervation 
functionally elevated the heart rates of the rescued mutants to those of littermate 
controls. 
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Figure 30. Shp2;Periostin-Cre;caMEK1 rescued mutants exhibit normalized 
cardiac sympathetic innervation. (A-C) TH IHC of P14 control (A), rescue (B), 
and mutant (arrow, C) cardiac ganglia demonstrating a restoration of TH 
expression in the rescued mutant ganglia. (D-F) TH IHC of P14 control (D), 
rescue (E), and mutant (F) left ventricle demonstrating increased TH-positive 
innervation in the rescued mutant ventricle (arrows in E). (G-I) Whole mount TH 
IHC showing the dorsal surface pattern of sympathetic innervation in a P14 
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control (G), rescued mutant (H), and mutant (I) heart. (Figure adapted from 
Lajiness et al., 2014). 
  
99 
 
 
Figure 31. Shp2;Periostin-Cre;caMEK rescued mutants exhibit normalized 
heart rates. ECG analysis of average heart rates of control, rescue, and mutant 
littermates at P14 (1-way ANOVA p=0.0113; Tukey’s multiple comparisons test: 
+/+ vs. rescue=non-significant, +/+ vs. cKO=significant (p<0.05), rescue vs. 
cKO=significant (p<0.05) n=5-20). Note that lineage-specific expression of 
caMEK1 restores the mutant heart rates. Error bars represent SEM. (Figure 
adapted from Lajiness et al., 2014).  
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One interesting aspect of the genetic intercross was that mixing the Shp2cKO 
model (on a predominantly C57BL/6 background) with the caMEK1 model (on a 
pure FVB/N background) shifted the basal heart rates of both control and mutant 
littermates (Figure 32). This is not surprising as mice of different genetic 
backgrounds have widely divergent basal heart rates163. Since the shift in basal 
heart rate affected all genotypes to the same extent and the relationship between 
control and Shp2 cKO heart rates was not altered, it was not investigated further. 
Rather, these data were considered evidence that the mechanism for cardiac 
sympathetic innervation described in this study holds true on more than one 
genetic background. 
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Figure 32. Genetic background effects on heart rate. Placing the C57BL/6 
mice on a mixed C57BL/6;FVB/N  background, equivalently altered basal heart 
rates in both Shp2 cKO and control mice. Average heart rates of P14 mice of 
either C57BL/6 or mixed (C57BL/6;FVB/N) genetic background demonstrating 
that both control and Shp2 cKO basal heart rates were similarly decreased on 
the mixed background (n=6-20). Error bars represent SEM. 
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Our studies revealed neurite outgrowth deficiency and overall diminished cardiac 
sympathetic innervation Shp2 cKOs. Taken together with the pERK-dependent 
rescue, these findings recapitulated previous in vitro work linking NGF, Shp2, 
pERK and sympathetic neuron differentiation. Thus, we propose a schematic 
detailing the likely signaling mechanism as explanation for these data (Figure 
33). Briefly, NGF binds to its receptor TrkA which is associated with a complex 
including Shp2. Propagation of signaling results in localization of Ras to the 
membrane where GDP is exchanged for GTP. Ras bound to GTP activates RAF 
via phosphorylation which continues the activating phosphorylation cascade 
through MEK and ERK. Once phosphorylated, ERK translocates to the nucleus 
where it promotes sympathetic neuron differentiation and neurite outgrowth.
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Figure 33. Proposed model for underlying signaling cascade responsible 
for the sympathetic innervation defects within Shp2 cKOs. Schematic based 
off of work detailed in Rosario et al., 200792. (Figure adapted from Lajiness et al., 
2014).  
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Despite enacting a complete rescue of the cardiac phenotype, the “rescued” 
Shp2;Periostin-Cre;caMEK mice still exhibited failure to thrive postnatallly with 
growth curves similar to that of non-rescued Shp2 cKOs (Figure 34). While half of 
the rescued mutants observed (n=16) lived past weaning, all were dead by P40 
(Figure 35). The doubling of the life-span of non-rescued mutants is significant; 
however, the persistence of lethality despite the rescue of heart rate indicates 
that not all aspects of the phenotype (particularly those with significant 
contributions to lethality) are addressed by normalizing pERK levels. 
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Figure 34. Growth curve of representative litter. Line graph of weight plotted 
from P7 to P13 of a litter of pups containing 7 controls (C1-C7), one non-rescued 
mutant (M1; Shp2 cKO), and two rescued mutants (R1 and R2; Shp2 
cKO;caMEK1). Notice that the growth curve of the rescued mutants matches the 
growth curve of the non-rescued mutant. This trend was consistently observed 
(n=6 litters).  
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Figure 35. Survival curve of mutants vs. rescued mutants vs. controls. Line 
graph of percent surviving pups over time for control (black), rescued mutant 
(blue), and non-rescued mutant (red) pups. Notice that the MEK rescue delays 
lethality but does not prevent it (n=16).  
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DISCUSSION 
 
The use of Periostin-Cre, which expresses Cre recombinase in post-migratory 
NC lineages from E10 onward, enabled us to selectively knock out expression of 
the Shp2 protein phosphatase during a previously unexplored window of NC 
development. Significantly, Shp2;Periostin-Cre mice were viable at birth in 
contrast to Shp2;Wnt-1-Cre mice which die at E13.5126. As Periostin-Cre is 
expressed in many of the same NC lineages as Wnt-1-Cre, we believe the timing 
of Cre recombinase expression and therefore loss of Shp2 to be critical for the 
phenotypic differences observed between the two mouse models. For example, 
loss of Shp2 at E8 results in loss of SCPs and immature SCs on peripheral 
nerves, structural craniofacial and cardiac abnormalities, diminished enteric 
innervation and incompatibility with postnatal life126. However, loss of Shp2 
expression just 2 days later (after NC cell migration) results in a viable pup with 
SCPs and immature SCs present on peripheral nerves but deficient myelination, 
normal craniofacial and cardiac structure, and diminished but present enteric 
innervation. These findings indicate that Shp2 may play an important role in the 
pre-migratory or migratory phase of NC development as many effects are 
decreased or absent when Shp2 is deleted in post-migratory NC. Significantly, 
we have shown that Periostin-Cre is a genetic tool that can be applied to 
investigate an important yet previously unexamined developmental time point. 
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The lack of embryonic mortality allowed us to investigate postnatal phenotypes. 
We observed that enteric innervation begins to look sparse by P7 and continues 
to dwindle as the phenotype associated with loss of Shp2 progresses. The 
significance of this observation has not yet been established; however, these 
gastrointestinal innervation defects could correlate to functional deficits such as 
motility abnormalities. 
 
Similarly, the diminished peripheral innervation was an interesting observation. In 
other models of NGF signaling cascade interruption, there is significantly reduced 
sensory innervation to target organs such as the skin and subcutaneous tissue 
as NGF is an important trophic and chemoattractant factor in these lineages27, 81, 
101. The functional significance of diminished peripheral innervation has not been 
investigated in detail in our mouse model; however, the lack of innervation of the 
tongue may indicate that Shp2 cKO pups have difficulty suckling and thus 
decreased nutrition may be a significant component of the failure to thrive 
observed.  
 
Despite the range of clinically applicable phenotypes observed, this study 
primarily focused on exploring the role of Shp2 and downstream pERK signaling 
in the context of sympathetic innervation of the developing heart. Specifically, 
sympathetic neuron differentiation as well as sympathetic innervation 
establishment and maintenance were investigated. While much is known about 
the molecular mechanisms regulating sympathetic neuron growth and 
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differentiation in vitro, many of these pathways had yet to be investigated in vivo. 
We generated a lineage specific KO of Shp2 that exhibits postnatal failure of 
sympathetic cardiac innervation. Furthermore, the fact that restoration of pERK 
levels through expression of a constitutively active upstream MEK1 rescued the 
cardiac innervation phenotype indicates that pERK signaling is necessary for 
peripheral sympathetic innervation in vivo. Shp2 has been shown in vitro to be a 
required intermediary linking NGF signaling to pERK elevation which is essential 
for sympathetic neuron differentiation85, 86, 92, 121, 122, 164-167. Our study now 
provides evidence that this holds true in vivo and has functional significance as 
diminished cardiac sympathetic innervation results in bradycardia. 
 
When the NGF-Shp2-ERK pathway is interrupted in model systems such as 
PC12 cells (cell line derived from rat adrenal pheochromocytoma that is often 
used as a model of sympathetic neuron survival and differentiation) and 
explanted superior cervical ganglia via pharmacological or genetic means, 
sympathetic neurons fail to differentiate (as indicated by the paucity of neurites 
projected from the cell body)85, 86, 92, 121, 122, 164-166. Some in vivo models have 
indicated an important role for NGF/MAPK signaling in sensory innervation 
patterning101. However, other groups have attempted to investigate the effect of 
Shp2 mutations on sympathetic innervation in vivo but were unable to 
recapitulate the in vitro results164. Thus, our Shp2 cKO is the first in vivo model to 
demonstrate that Shp2 and subsequent pERK elevation are required for 
sympathetic innervation of the developing heart. 
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It was interesting to note that although Periostin-Cre is expressed from E10.5 
onward, phenotypic differences between Shp2 cKOs and controls were not 
observed until after birth. This could be due to the fact that NGF and its 
downstream signaling is not required for sympathetic innervation until E16.590. 
However, in the absence of an inducible Cre to temporally vary when Shp2 is 
deleted we cannot exclude the possibility that NC progenitors are altered or 
misspecified early in development and the effects are not manifested until after 
birth. This is a limitation of the current study and is an avenue of future research 
when the appropriate genetic tools become available. 
 
While global cardiac sympathetic innervation was diminished in cKOs, it was 
interesting to note that the TH-positive intrinsic cardiac ganglia exhibited 
decreased neurite outgrowth and TH expression. This emphasizes that these 
structures are subject to the influences of Shp2 and pERK signaling. 
Furthermore, in the context of sinus bradycardia, our findings reinforce the 
functional role of TH-positive cardiac ganglia in the “heart brain” as well as the 
idea that they are involved in heart rate regulation particularly in the first 2-3 
weeks of life36, 37, 39, 42. The dearth of axonal projections emanating from these 
ganglia suggest that there is a failure of sympathetic neurons to differentiate or to 
maintain their differentiated state in Shp2 cKOs. The loss of sympathetic-specific 
TH expression despite continued expression of the generic neuronal marker 
NSβT further supports this conclusion. Together, these data suggest that the 
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NGF signaling pathway which is responsible for sympathetic neuron 
differentiation and maintenance during the early postnatal period may be the 
underlying mechanism for the altered sympathetic innervation observed in Shp2 
cKO hearts. 
 
Aberrant expression of embryonic sympathetic neuron differentiation transcription 
factors such as Phox2a and 2b which regulate TH and dopamine β-hydroxylase 
expression67 further supports this hypothesis. However, as only a few time points 
were investigated, it is not known if Phox2a and 2b expression is appropriately 
downregulated in Shp2 cKOs at birth and then aberrantly re-expressed later in 
the postnatal period or if expression is simply never appropriately downregulated. 
The former would imply that sympathetic neurons differentiate initially and then 
dedifferentiate postnatally whereas the latter scenario would indicate that the 
cardiac sympathetic neurons never appropriately differentiate. Distinguishing 
these events could be investigated by performing in situ hybridization to examine 
late embryonic and early postnatal expression of Phox2a and 2b which would 
shed light on Shp2 and pERK’s roles in establishing versus maintaining a 
differentiated state in sympathetic neurons. 
 
Additionally, the absence of apoptotic cells in mutant sympathetic ganglia 
emphasizes the fact that MAPK signaling is essential for differentiation but not for 
the survival of sympathetic neurons. While there have been reports that MAPK 
signaling can play a role in neuronal survival particularly in the context of 
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cytotoxic injury by agents such as cytosine arabinoside (AraC)91, 168, 169, NGF is 
thought to maintain a basal level of sympathetic neuron survival via PI3K/AKT 
signaling which is not disturbed in our model. Thus, although these Shp2-
regulated protein kinases (including ERK) have pleotropic effects on the cell, they 
likely elicit some of their effects by regulating downstream mediators of 
sympathetic nervous system homeostatic gene expression. 
 
Functionally, we have demonstrated that Shp2-dependent sympathetic deficiency 
leads to sinus bradycardia. No other abnormalities or arrhythmias were observed 
in the ECG traces to indicate any intrinsic cardiac pathology. Since the P-wave is 
consistently present in both control and Shp2 cKO traces and lasts for the same 
duration, these data indicate that the SA node is appropriately initiating the action 
potential which is efficiently disseminated throughout the atrial myocardium 
resulting in the expected pattern of depolarization. Furthermore, the lack of 
prolongation of PR intervals throughout the majority of ages investigated 
indicates that the AV node is functioning appropriately. The minor PR 
prolongation observed at P17 is most likely a product of significantly decreased 
heart rates and, importantly, never progresses from 1st degree heart block to any 
form of arrhythmia. The normal QRS complex indicates that the action potential 
is efficiently transferred throughout the Purkinje fiber network with no conduction 
delays or bundle branch blocks observed. Because this is a 3-lead ECG as 
opposed to the more sophisticated 12-lead ECGs utilized in human studies, we 
cannot examine parameters such as axis shifts. However, with the information 
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we have collected, there is no reason to suspect that any conduction abnormality 
or axis shift would be observed as a result of the loss of Shp2 expression. 
 
As there is diminished sympathetic innervation in the Shp2 cKO heart, and thus 
less catecholamines (i.e. norepinephrine) released to maintain an elevated heart 
rate, we reason that this deficiency is the direct cause of the bradycardia 
observed. Therefore, we hypothesized that delivering an exogenous β-adrenergic 
agonist (isoproterenol) would stimulate both the control and Shp2 cKO heart to 
beat faster. Since isoproterenol did increase both the control and Shp2 cKO 
heart rates equivalently, we were able to conclude that the mutant heart is 
functionally capable of responding to catecholamines and maintaining a rapid 
heart rate (decreasing the likelihood of conduction or structural defects as a 
cause of the bradycardia). This finding also indicates that Shp2 expression in 
post-migratory NC cells is not required for the heart to respond to 
catecholamines. Histological examination of the SA node indicated that the node 
was present and appropriately expressing the pacemaker cell marker HCN4. 
This finding of normal appearing histology is consistent with the presence of a 
regularly occurring P-wave on the ECG traces. If the SA node were structurally 
compromised to the point that the “pacemaker” function of the heart had been 
taken up by a secondary pacemaker such as the AV node, the heart rate would, 
indeed, be slower; however, the P-wave would be absent which is not the case in 
our model. Together, these data further exclude intrinsic SA node dysfunction as 
the primary cause of bradycardia in the Shp2 cKOs. 
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As fibroblasts serve as the insulating component for the intrinsic conduction 
system of the heart and are affected by the genetic modification driven by 
Periostin-Cre, alterations in fibroblast number or localization were investigated. 
No aberrancies in either parameter were found in Shp2 cKO cardiac fibroblasts 
and the fibroblasts appropriately expressed αsmooth muscle actin. While cardiac 
fibroblasts, particularly in neonates, express αsmooth muscle actin ,one 
important consideration when using αsmooth muscle actin as an indicator of 
cardiac fibroblasts is that injury to the heart causes cardiac fibroblasts 
differentiate into myofibroblasts which drastically increase expression of αsmooth 
muscle actin (reviewed in Lajiness et al., 2013151). As neither structural injury to 
the heart nor fibrosis is present in our model, we do not think that this fact alters 
the interpretation of our data. Importantly, the number of LacZ-positive (i.e. 
genetically modified) cardiac fibroblasts decreased with age. Since the number of 
fibroblasts affected is decreasing as the bradycardia is worsening, it is not likely 
that cardiac fibroblasts are involved in the pathomechanism of the bradycardia. 
 
Similarly, the distribution of cardiac sympathetic innervation was investigated. 
Specifically, the proportion of TH-positive fibers in the epicardial region of the 
myocardium (the “outside” surface of the heart) compared to the endocardial 
region of the myocardium (the “inside” surface of the heart) was of particular 
interest. In a “normal” heart there is more sympathetic innervation in the 
epicardium compared to the endocardium. Absence of this epicardial-to-
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endocardial gradient has been associated with bradycardia in other mouse 
models97. Despite the global decrease in cardiac sympathetic innervation of Shp2 
cKO hearts, the fact that the epicardial-to-endocardial gradient was intact in all 
ages examined indicates that this is not a contributing factor to the sinus 
bradycardia observed in Shp2 cKOs. Furthermore, as administration of atropine 
to inhibit the parasympathetic innervation did not elevate heart rate, increased 
parasympathetic tone is not responsible for the slowed heart rate. Therefore, 
having eliminated the other most likely explanations, we concluded that the 
diminished sympathetic tone is the direct cause of the sinus bradycardia 
observed in Shp2 cKOs. This hypothesis was further verified by rescuing the 
sympathetic innervation phenotype by conditionally expressing caMEK1 which 
abolished the sinus bradycardia. 
 
MEK1 is an ideal target for a genetic rescue of our model as the only known 
substrate of MEKs are ERK1/2, and reciprocally, the only known activators of 
ERK1/2 are MEK1/2121. Both MEK1 and MEK2 are known to activate ERKs; 
however, MEK1 has been more extensively studied and is considered the more 
physiologically relevant isoform particularly downstream of RAS. In vitro studies 
have revealed that MEK1 but not MEK2 associates with RAS in a signaling 
complex when NIH 3T3 cells are serum starved and then stimulated with fetal 
calf serum170. Specifically, in PC12 cells an inactivating mutation in MEK1 blocks 
sympathetic differentiation while activating mutations facilitate neurite outgrowth 
even in the presence of dominant-negative Shp2 or in the absence of NGF86, 122. 
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Introduction of caMEK1 driven by the same conditional system as our Shp2 cKO, 
allowed us to simultaneously delete Shp2 and express caMEK in post-migratory 
NC. Significantly, this model resulted in a physiological increase in pERK levels 
(restored to control levels) as unchecked elevation of pERK can result in cardiac 
valvular and septal abnormalities171. 
 
The spatiotemporal precision of this genetic model has allowed us to begin to 
parse out the ERK-dependent from the ERK-independent effects of Shp2 cKO. 
The rescued mutants (Shp2;Periostin-Cre;caMEK) still exhibit failure to thrive and 
eventually die (100% lethality by P40) although a significant portion (~50%) 
survive past weaning whereas all non-rescued mutants (Shp2 cKOs) die prior to 
P21. The lack complete rescue of lethality indicates that there may be both ERK-
dependent and ERK–independent mechanisms contributing to the eventual 
death of the organism. For example, the altered peripheral and enteric 
innervation, although not the focus of this study, could be contributing factors to 
lethality in both the cKO and rescued model. Specifically, in addition to following 
a similar pattern of growth, rescued mutants do noticeably exhibit the same gait 
abnormalities and grasping phenotype observed in Shp2 cKOs. This phenotype 
is observed as early as P7 in both genotypes. 
 
It is possible that these aspects are not rescued because they are not dependent 
on pERK levels and that a different molecular mechanism is the cause. An 
alternative explanation is that there is not complete rescue due to the fact that 
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dynamic pERK regulation cannot be achieved through constitutive expression of 
caMEK1. This genetic model effectively increases basal pERK levels to that seen 
in controls; however, it also separates the regulation of pERK levels from NGF 
and other growth factor signaling. This itself can have physiologic ramifications 
and must be carefully considered as a confounding factor. 
 
Significantly, our findings indicate that establishment of sympathetic innervation 
of the heart is an ERK-dependent event as all aspects of the cardiac innervation 
phenotype observed in the Shp2 cKO were rescued by lineage-restricted 
caMEK1. This model provides a useful tool in which to identify lineage-specific 
proximate targets of Shp2 during autonomic innervation and establishment of a 
mature functioning cardiovascular system.  
 
Through lending mechanistic insight to early sympathetic innervation and heart 
rate regulation, our Shp2 cKO model also allows for investigation of how the loss 
of Shp2 function in diseases such as LS can lead to the ECG abnormalities 
characteristic of the syndrome108, 112. While these abnormalities are not extremely 
well characterized and often complicated by structural cardiac defects112, 114, 172, 
173, our cKO mouse provides an opportunity to study Shp2’s spatiotemporal role 
in establishing aberrant ECG patterning in isolation from compounding structural 
cardiac defects. It is important to remember, however, that our Shp2 cKO is not a 
model for LS as LS exhibits a mutation in the Shp2 protein expressed from one 
of the two alleles encoding the protein as opposed to absence of Shp2 protein 
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expression all together. Additionally, it is thought that LS mutant Shp2 acts in a 
complicated mechanism possibly involving dominant negative effects as the 
catalytically inactive version of Shp2 is in the open conformation (traditionally the 
active conformation) which may allow it to outcompete the normal Shp2 for 
binding sites at RTKs102, 108. Furthermore, the LS mutation occurs in all cells from 
conception onward. Despite these differences, the knowledge gained about NC 
biology and how it contributes to the establishment and maintenance of 
sympathetic innervation in the heart though these studies can be applied to many 
diseases including LS. In addition, these studies contribute to our general 
knowledge of sympathetic innervation and the various interruptions to its 
development that can occur embryonically as well as postnatally. 
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FUTURE STUDIES 
 
Future studies will focus on investigating aspects of the Shp2 cKO (with and 
without the MEK1 rescue) phenotypes potentially involved in lethality such as the 
altered enteric innervation and peripheral innervation abnormalities initially 
observed at P7. 
 
Further investigation of enteric innervation will involve whole-mount NSβT IHC of 
gut sections at various time points throughout development (P7, P13, P15, and 
P18 have already been investigated so this work would primarily focus on earlier 
stages to establish when the phenotype is first observed). This will allow for a 
longitudinal approach to examine the progression of the phenotype over time. 
Furthermore, incorporation of functional studies to ascertain if the diminished 
enteric innervation results in abnormal or protracted peristaltic activity may be 
informative. Also, the etiology of enteric ganglia absence would be interesting to 
examine. Evaluating whether this is due to decreased proliferation or apoptosis 
can be accomplished with IHC. An in-depth histological analysis of the many 
layers of intestinal tissue may be useful even if only to eliminate structural 
abnormalities as a pathomechanism for the failure to thrive phenotype observed 
postnatally. 
 
In addition, pups were observed to have gait abnormalities and grasping 
phenotypes often associated with myelination defects107, 174-177. These were 
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observed at P7, prior to weight loss or heart rate abnormalities. As the 3.9kb 
Periostin promoter has been shown to be expressed in Schwann cells by E14137 
and Shp2 is known to play an important role in myelination101, 126, 134, 135, the 
potential presence of a myelination phenotype in the Shp2 cKOs was 
investigated. To examine a possible myelination defect, we explored whether or 
not Schwann cell precursors (SCPs) migrate and immature SCs persist on 
peripheral nerves embryonically. Hematoxylin and eosin (H&E) stained sections 
of embryonic dorsal root ganglia indicated that, indeed, SCPs migrated and 
immature SCs were present on peripheral nerves at E14.5 and 16.5 (Figure 36). 
Further investigation revealed that although SCs are present on peripheral 
nerves, preliminary data suggest that the myelin generated by mutant SCs is 
much thinner in trigeminal (Figure 37) as well as sciatic (Figure 38) nerves. 
Additionally, axonal loss was observed in the sciatic nerve of Shp2 cKO pups 
(Figure 38). Interestingly, expression of caMEK1 appears to rescue the 
myelination phenotype in the trigeminal nerve (Figure 37), but does not alter the 
myelination nor the axonal loss in the sciatic nerve (Figure 38). These findings, 
although preliminary, may explain the gait abnormalities and most likely 
contribute to the failure to thrive phenotype that eventually leads to lethality. 
However, it is important to remember that hypomyelination, although sometimes 
associated with failure to thrive and early postnatal lethality, can also be 
compatible with life as seen in the Trembler mice (a model of Charcot-Marie-
Tooth disease)178, 179.  
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Figure 36. Immature SCs are present on Shp2 cKO peripheral nerves 
embryonically. (A) E16.5 control dorsal root ganglia (low mag, top panel; high 
mag, lower panel) showing migration of SCPs onto peripheral nerves as 
evidenced by hemotoxylin positive nuclei present (see arrows). (B) E16.5 mutant 
dorsal root ganglia illustrating that Shp2 cKOs also have SCPs present on 
peripheral nerves embryonically (see arrows; n=2). 
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Figure 37. A myelination defect is observed in trigeminal nerves of Shp2 
cKOs and appears to be rescued by caMEK1 expression. (A) P17 control EM 
of trigeminal nerve at low power (2,900X; top panel) and high power (30,000X; 
lower panel). (B) P17 Shp2 cKO EM of trigeminal nerve at low power (2,900X; 
top panel) and high power (30,000X; lower panel). (C) P17 rescued mutant EM of 
trigeminal nerve at low power (2,900X; top panel) and high power (30,000X; 
lower panel). Notice the thin layers of myelin in the cKO compared to the thick, 
cohesive myelin in the control and rescued mutant (n=2-3). [IU EM core 
processed nerve tissue and assisted in collecting images]. 
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Figure 38. Diminished myelination and axonal loss observed in sciatic 
nerves of Shp2 cKOs and rescued mutants. (A-C) Thick section of P17 control 
(A), Shp2 cKO (B), and rescued mutant (C) sciatic nerve (cross-section). Note 
the dark uniform myelination surrounding individual axons in the control that is 
largely absent from the mutant and rescued mutant nerve. (D-F) TEM image of 
P17 control (D), Shp2 cKO (E), and rescued mutant (F) sciatic nerve (2,900 X). 
Note the predominance of unmyelinated/minimally myelinated axons in the Shp2 
cKO and rescued mutant samples. Also, there is significant axonal loss in the 
Shp2 cKO (E, arrows) and rescued mutant (F, arrows) which is not present in the 
control nerve. (G-I) TEM image of P17 control (G), Shp2 cKO (H), and rescued 
mutant (I) sciatic nerve (11,000 X). Note the predominance of 
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unmyelinated/minimally myelinated axons in the Shp2 cKO and rescued mutant 
samples (n=2-3). [IU EM core processed nerve tissue, assisted in collecting 
imagaes, and provided thick sections]. 
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Several preliminary studies have already been performed to begin to parse out 
the myelination defects present in the Shp2 cKO and Shp2;Periostin-
Cre;caMEK1 mouse models. Kelly Monk, PhD at Washington University has 
been a valuable collaborator and has advised on planning future experiments as 
well as interpretation of TEM data. To date, I have collected samples of 
trigeminal and sciatic nerves at P17 and examined them via TEM. Preliminary 
analysis indicates that there is a myelination defect observed in Shp2 cKOs 
which appears to be rescued by expression of caMEK1 in the trigeminal nerve; 
however, diminished myelination as well as axonal loss is observed in the sciatic 
nerves of both non-rescued and rescued mutants which most likely accounts for 
the persistence of the gait abnormalities in the rescued mutants. 
 
At present, these data only represent investigation of two or three animals of 
each genotype and are still preliminary. Several caveats need to be addressed to 
complete the myelination story. For example, it is still unclear as to whether the 
observed myelination phenotype is a primary or secondary effect particularly as 
the samples were harvested at P17 when the Shp2 cKOs are already 
experiencing significantly diminished health. Furthermore, despite the fact that 
the Periostin promoter that drives Cre recombinase expression in our model has 
been shown to be expressed in SCs as early as E14137, the recombination 
efficiency in SCs of the trigeminal nerve and sciatic nerve has not been 
investigated in the early postnatal stage. Notwithstanding the preliminary nature 
of these studies, these findings of decreased myelination and axonal loss in the 
126 
 
peripheral nervous system serve to place our cardiac focused story in the overall 
context of the entire organism. The advantage of in vivo studies as compared to 
in vitro studies is the context. There are only so many aspects of biochemical 
signaling pathways and physiology that can be accurately replicated in vitro. The 
body of recent literature on cardiac innervation suggests that there are complex 
interactions between sympathetic, parasympathetic, and sensory neurons within 
the “heart brain” which serve to regulate the heart’s function36-42. While the 
sympathetic innervation of the heart is not myelinated, a subset of the sensory 
innervation is. Therefore, thoroughly characterizing the myelination phenotype of 
Shp2 cKOs can further inform what we already know about the cardiac 
innervation in this model. 
 
Future work could focus on collecting samples at earlier time points (Dr. Monk 
has suggested P0 (before myelination is really established) and P7 (an 
intermediate time point)). Examination of these developmental time points will 
shed light on the process that leads to the myelination defect. Again, proliferation 
and apoptosis studies via IHC may be informative as to the etiology of this loss. 
Furthermore, Dr. Monk has suggested staining for important myelin proteins such 
as P0 to investigate the structural integrity of the myelin that is present as the 
separation of the myelin layers observed in Figure 37 may be indicative of a 
structural defect in the myelin layers. However, it is also possible that this 
separation observed is an effect of processing and must be investigated further. 
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Functional studies may also be incorporated to evaluate the motility phenotypes 
observed in both rescued and non-rescued mutants. Additionally, nerve 
conduction studies to quantitatively determine the rate of action potential 
transmission through an isolated peripheral nerve such as the sciatic would yield 
critical information as to how the structural phenotype observed by TEM is 
directly affecting the animal in terms of action potential propagation. This is also 
one of the few tests that would be capable of detecting an intermediate 
phenotype or partial rescue in the rescued mutants due to its quantitative nature. 
 
Collectively these histological and functional investigations along with molecular 
analyses designed to probe signaling pathways involved in the observed 
phenotypes will serve to further delineate the ERK-dependent versus ERK-
independent effects observed in our Shp2 cKO. The gastrointestinal and 
myelination manifestations of Shp2 loss are of particular interest due to their 
clinical implications. Furthermore, the fact that abnormalities in both the enteric 
and peripheral nervous system are much more severe in early models of NC 
Shp2 loss (specifically Wnt-1-Cre driven deletion126) underscores the utility of 
Periostin-Cre as a genetic tool to examine complex developmental processes in 
the NC. 
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